Submit Data |  Help |  Video Tutorials |  News |  Publications |  FTP Download |  REST API |  Citing RGD |  Contact   

CHEBI ONTOLOGY - ANNOTATIONS

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:epidermal growth factor receptor antagonist
go back to main search page
Accession:CHEBI:74440 term browser browse the term
Definition:An antagonist at the epidermal growth factor receptor.
Synonyms:related_synonym: EGFR antagonoist;   EGFR antagonoists;   EGFR inhibitor;   EGFR inhibitors;   epidermal growth factor receptor antagonists;   epidermal growth factor receptor inhibitor;   epidermal growth factor receptor inhibitors
 xref: Wikipedia:Epidermal_growth_factor_receptor


show annotations for term's descendants           Sort by:
 
dacomitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Egfr epidermal growth factor receptor multiple interactions ISO dacomitinib inhibits the reaction [EGFR protein results in increased phosphorylation of EGFR protein] CTD PMID:27491023 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
erlotinib hydrochloride term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [ABCG2 gene mutant form results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in decreased susceptibility to Mitoxantrone]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 protein results in increased export of Methotrexate]; Erlotinib Hydrochloride inhibits the reaction [ABCG2 results in increased export of Methotrexate] CTD PMID:18829547, PMID:19232821 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Acaca acetyl-CoA carboxylase alpha increases phosphorylation ISO Erlotinib Hydrochloride results in increased phosphorylation of ACACA protein CTD PMID:23707608 NCBI chr10:71,519,392...71,719,910
Ensembl chr10:71,536,533...71,719,910
JBrowse link
G Adgre1 adhesion G protein-coupled receptor E1 multiple interactions ISO [Interleukin 1 Receptor Antagonist Protein co-treated with Erlotinib Hydrochloride] results in decreased expression of ADGRE1 protein CTD PMID:27738319 NCBI chr 9:9,431,888...9,585,883
Ensembl chr 9:9,431,860...9,585,865
JBrowse link
G Akt1 AKT serine/threonine kinase 1 decreases phosphorylation
multiple interactions
ISO Erlotinib Hydrochloride results in decreased phosphorylation of AKT1 protein
Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]
CTD PMID:21195724, PMID:30623574 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Apaf1 apoptotic peptidase activating factor 1 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of APAF1 mRNA CTD PMID:29274334 NCBI chr 7:31,699,309...31,784,192
Ensembl chr 7:31,699,885...31,784,192
JBrowse link
G Areg amphiregulin affects response to substance ISO AREG protein affects the susceptibility to Erlotinib Hydrochloride CTD PMID:18980991 NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
JBrowse link
G Arf1 ADP-ribosylation factor 1 decreases response to substance ISO ARF1 mRNA results in decreased susceptibility to Erlotinib Hydrochloride CTD PMID:23125191 NCBI chr10:45,562,700...45,579,214
Ensembl chr10:45,563,547...45,579,029
JBrowse link
G Atf4 activating transcription factor 4 increases expression EXP Erlotinib Hydrochloride results in increased expression of ATF4 protein CTD PMID:24768708 NCBI chr 7:121,480,723...121,482,781
Ensembl chr 7:121,480,723...121,482,772
JBrowse link
G Atg5 autophagy related 5 decreases response to substance
increases expression
ISO ATG5 protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased expression of ATG5 protein
CTD PMID:21655094, PMID:23917044 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Atg7 autophagy related 7 increases expression ISO Erlotinib Hydrochloride results in increased expression of ATG7 protein CTD PMID:21655094 NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
JBrowse link
G Atm ATM serine/threonine kinase multiple interactions ISO Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATM mRNA] CTD PMID:29274334 NCBI chr 8:58,015,938...58,119,973
Ensembl chr 8:58,015,940...58,120,045
JBrowse link
G Atr ATR serine/threonine kinase multiple interactions
increases expression
ISO Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of ATR mRNA]
Erlotinib Hydrochloride results in increased expression of ATR mRNA
CTD PMID:29274334 NCBI chr 8:103,673,578...103,770,886
Ensembl chr 8:103,673,411...103,770,947
JBrowse link
G Axl Axl receptor tyrosine kinase decreases response to substance
multiple interactions
ISO AXL results in decreased susceptibility to Erlotinib Hydrochloride
[GSK 1363089 results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride; [MP470 results in decreased activity of AXL protein] which results in increased susceptibility to Erlotinib Hydrochloride
CTD PMID:22751098 NCBI chr 1:82,550,892...82,580,761
Ensembl chr 1:82,549,420...82,580,761
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAD mRNA] CTD PMID:29274334 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions ISO Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of BAX mRNA] CTD PMID:29274334 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bbc3 Bcl-2 binding component 3 multiple interactions
increases expression
ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in increased expression of BBC3 mRNA; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of BBC3 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of BBC3 protein] CTD PMID:25895606, PMID:29274334 NCBI chr 1:78,261,491...78,267,802 JBrowse link
G Bcl2 BCL2, apoptosis regulator increases expression
multiple interactions
ISO Erlotinib Hydrochloride results in increased expression of BCL2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2 protein
[Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BCL2 mRNA; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2 protein]
CTD PMID:23894143, PMID:29274334 NCBI chr13:26,605,426...26,769,374
Ensembl chr13:26,605,426...26,769,374
JBrowse link
G Bcl2l11 BCL2 like 11 multiple interactions
increases expression
ISO Harmine promotes the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L11 protein] CTD PMID:30171258 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Bcl2l2 Bcl2-like 2 increases expression
multiple interactions
ISO Erlotinib Hydrochloride results in increased expression of BCL2L2 mRNA; Erlotinib Hydrochloride results in increased expression of BCL2L2 protein
[Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased expression of BCL2L2 protein]
CTD PMID:23894143 NCBI chr15:33,543,774...33,549,165
Ensembl chr15:33,544,312...33,549,164
JBrowse link
G Becn1 beclin 1 decreases response to substance ISO BECN1 protein results in decreased susceptibility to Erlotinib Hydrochloride CTD PMID:23917044 NCBI chr10:89,209,944...89,225,297
Ensembl chr10:89,209,940...89,225,297
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression
ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of BIRC5 mRNA; Erlotinib Hydrochloride inhibits the reaction [betulinic acid results in decreased expression of BIRC5 protein]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in decreased expression of BIRC5 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of BIRC5 protein] CTD PMID:25895606, PMID:29274334, PMID:30136359 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] CTD PMID:25981168 NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
JBrowse link
G Brca1 BRCA1, DNA repair associated multiple interactions ISO [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein CTD PMID:23548265 NCBI chr10:89,394,821...89,455,093
Ensembl chr10:89,394,803...89,454,681
JBrowse link
G Casp3 caspase 3 increases cleavage
multiple interactions
increases activity
ISO Erlotinib Hydrochloride results in increased cleavage of CASP3 protein
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein
Erlotinib Hydrochloride results in increased activity of CASP3 protein
Erlotinib Hydrochloride promotes the reaction [resveratrol results in increased activity of CASP3 protein]; resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased activity of CASP3 protein]
CTD PMID:23125191, PMID:25895606, PMID:30171258 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of CCL2 mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of CCL2 mRNA CTD PMID:27738319 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of CCNB1 mRNA CTD PMID:29274334 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased expression of CCND1 protein] CTD PMID:19168569 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Cd69 Cd69 molecule decreases expression ISO Erlotinib Hydrochloride results in decreased expression of CD69 protein CTD PMID:21195724 NCBI chr 4:163,041,147...163,049,065
Ensembl chr 4:163,041,141...163,049,084
JBrowse link
G Cdh1 cadherin 1 multiple interactions
decreases expression
ISO
EXP
Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in increased degradation of CDH1 protein]; Erlotinib Hydrochloride results in decreased glycosylation of and results in increased degradation of CDH1 protein
Erlotinib Hydrochloride results in decreased expression of CDH1 mRNA; Erlotinib Hydrochloride results in decreased expression of CDH1 protein
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]
CTD PMID:22223758, PMID:24768708 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cdk4 cyclin-dependent kinase 4 decreases phosphorylation ISO Erlotinib Hydrochloride results in decreased phosphorylation of CDK4 protein CTD PMID:21195724 NCBI chr 7:70,345,971...70,352,689
Ensembl chr 7:70,349,863...70,352,418
JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
decreases expression
ISO betulinic acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of CDK6 protein] CTD PMID:30136359 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions
ISO Erlotinib Hydrochloride results in increased expression of CDKN1A mRNA
Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of CDKN1A mRNA]
CTD PMID:29274334 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Chfr checkpoint with forkhead and ring finger domains multiple interactions ISO CHFR protein affects the susceptibility to [Cisplatin co-treated with Erlotinib Hydrochloride] CTD PMID:20705357 NCBI chr12:52,562,594...52,596,162
Ensembl chr12:52,562,597...52,596,076
JBrowse link
G Chrdl2 chordin-like 2 multiple interactions ISO [gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CHRDL2 protein CTD PMID:24979617 NCBI chr 1:165,008,997...165,036,431
Ensembl chr 1:165,008,912...165,036,435
JBrowse link
G Csf3 colony stimulating factor 3 increases secretion ISO Erlotinib Hydrochloride results in increased secretion of CSF3 protein CTD PMID:27738319 NCBI chr10:86,616,785...86,619,160
Ensembl chr10:86,616,785...86,619,157
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
decreases expression
ISO [betulinic acid co-treated with Erlotinib Hydrochloride] results in decreased expression of CTNNB1 protein
Erlotinib Hydrochloride results in decreased expression of CTNNB1 protein
CTD PMID:30136359 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Cxcl11 C-X-C motif chemokine ligand 11 multiple interactions ISO [gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of CXCL11 protein CTD PMID:24979617 NCBI chr14:17,195,395...17,198,170
Ensembl chr14:17,195,014...17,198,291
JBrowse link
G Cyp19a1 cytochrome P450, family 19, subfamily a, polypeptide 1 decreases activity ISO Erlotinib Hydrochloride results in decreased activity of CYP19A1 protein CTD PMID:26141389 NCBI chr 8:58,744,849...58,772,408
Ensembl chr 8:58,744,849...58,772,408
JBrowse link
G Cyp2b3 cytochrome P450, family 2, subfamily b, polypeptide 3 increases expression ISO Erlotinib Hydrochloride results in increased expression of CYP2B6 mRNA CTD PMID:30364229 NCBI chr 1:83,163,103...83,236,615
Ensembl chr 1:83,163,079...83,236,615
JBrowse link
G Cyp51 cytochrome P450, family 51 increases response to substance ISO CYP51A1 mRNA results in increased susceptibility to Erlotinib Hydrochloride CTD PMID:23125191 NCBI chr 4:27,175,564...27,194,018
Ensembl chr 4:27,175,243...27,194,018
JBrowse link
G Ddit3 DNA-damage inducible transcript 3 increases expression
multiple interactions
ISO
EXP
Erlotinib Hydrochloride results in increased expression of DDIT3 protein
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of CDH1 protein]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]
CTD PMID:24768708 NCBI chr 7:70,578,564...70,585,074
Ensembl chr 7:70,580,198...70,585,084
JBrowse link
G Dennd6b DENN domain containing 6B decreases expression ISO Erlotinib Hydrochloride results in decreased expression of DENND6B mRNA CTD PMID:27720938 NCBI chr 7:130,162,728...130,178,282
Ensembl chr 7:130,164,675...130,176,696
JBrowse link
G Dusp1 dual specificity phosphatase 1 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of DUSP1 mRNA CTD PMID:27738319 NCBI chr10:16,970,642...16,973,425
Ensembl chr10:16,970,626...16,973,418
JBrowse link
G Egf epidermal growth factor multiple interactions ISO
EXP
Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to gemcitabine]]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in decreased susceptibility to Crizotinib]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]
CTD PMID:21613822, PMID:21787763, PMID:22553343, PMID:25625231, PMID:27427493, PMID:30364229 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor affects response to substance
decreases expression
decreases phosphorylation
decreases activity
multiple interactions
decreases response to substance
ISO EGFR protein affects the susceptibility to Erlotinib Hydrochloride; EGFR protein mutant form affects the susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in decreased expression of EGFR protein modified form
Erlotinib Hydrochloride results in decreased phosphorylation of EGFR protein
Erlotinib Hydrochloride results in decreased activity of EGFR protein
[Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein; [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased phosphorylation of BRCA1 protein; EGFR gene mutant form results in increased susceptibility to [gemcitabine co-treated with Cisplatin co-treated with Erlotinib Hydrochloride]; Erlotinib Hydrochloride inhibits the reaction [Arsenic Trioxide results in increased phosphorylation of and results in increased activity of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]; Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [Deoxycholic Acid results in decreased glycosylation of and results in decreased expression of EGFR protein]; Erlotinib Hydrochloride promotes the reaction [EGF protein binds to EGFR protein]; Erlotinib Hydrochloride results in decreased activity of and results in decreased phosphorylation of EGFR protein; Erlotinib Hydrochloride results in decreased glycosylation of and results in decreased expression of EGFR protein
EGFR protein mutant form results in decreased susceptibility to Erlotinib Hydrochloride
CTD PMID:12907618, PMID:16407879, PMID:16891461, PMID:19168569, PMID:21080748, PMID:21541241, PMID:21787763, PMID:22223758, PMID:22751098, PMID:23099361, PMID:23440206, PMID:23548265, PMID:23894143, PMID:25625231, PMID:26455392, PMID:28101945, PMID:30136359, PMID:30364229, PMID:30623574 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Eif2s1 eukaryotic translation initiation factor 2 subunit alpha increases expression EXP Erlotinib Hydrochloride results in increased expression of EIF2S1 protein modified form CTD PMID:24768708 NCBI chr 6:102,048,372...102,073,041
Ensembl chr 6:102,048,372...102,073,041
JBrowse link
G Elk1 ETS transcription factor ELK1 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased activity of ELK1 protein]; Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of ELK1 protein] CTD PMID:25625231, PMID:30364229 NCBI chr  X:1,287,875...1,304,822
Ensembl chr  X:1,297,099...1,304,822
JBrowse link
G Erbb3 erb-b2 receptor tyrosine kinase 3 decreases response to substance ISO ERBB3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride CTD PMID:23125191 NCBI chr 7:2,989,202...3,010,610
Ensembl chr 7:2,989,340...3,010,350
JBrowse link
G Foxg1 forkhead box G1 multiple interactions
decreases expression
ISO Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of FOXG1 protein]
Erlotinib Hydrochloride results in decreased expression of FOXG1 protein
CTD PMID:26455392 NCBI chr 6:69,971,227...69,974,037
Ensembl chr 6:69,971,227...69,974,037
JBrowse link
G Foxo3 forkhead box O3 decreases phosphorylation ISO Erlotinib Hydrochloride results in decreased phosphorylation of FOXO3 protein CTD PMID:23099361 NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
JBrowse link
G Gdf15 growth differentiation factor 15 multiple interactions ISO [gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of GDF15 protein CTD PMID:24979617 NCBI chr16:20,555,395...20,557,978
Ensembl chr16:20,555,395...20,557,978
JBrowse link
G Gmpr guanosine monophosphate reductase decreases expression ISO Erlotinib Hydrochloride results in decreased expression of GMPR mRNA CTD PMID:27720938 NCBI chr17:19,543,274...19,580,929
Ensembl chr17:19,543,275...19,580,929
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases expression ISO Erlotinib Hydrochloride results in decreased expression of GSK3B protein modified form CTD PMID:30136359 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G H2ax H2A.X variant histone multiple interactions
increases expression
ISO Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of H2AX protein modified form]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of H2AX protein modified form] CTD PMID:25895606 NCBI chr 8:48,665,652...48,666,981
Ensembl chr 8:48,665,652...48,666,981
JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [HBEGF protein results in decreased susceptibility to crizotinib] CTD PMID:22553343 NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
JBrowse link
G Ifitm3 interferon induced transmembrane protein 3 decreases expression ISO Erlotinib Hydrochloride results in decreased expression of IFITM3 mRNA CTD PMID:27720938 NCBI chr 1:213,810,712...213,811,821
Ensembl chr 1:213,810,696...213,811,901
JBrowse link
G Ifng interferon gamma decreases secretion ISO Erlotinib Hydrochloride results in decreased secretion of IFNG protein CTD PMID:21195724 NCBI chr 7:61,337,383...61,341,419
Ensembl chr 7:61,337,381...61,341,419
JBrowse link
G Il17f interleukin 17F increases expression ISO
EXP
Erlotinib Hydrochloride results in increased expression of IL17F mRNA CTD PMID:24768708 NCBI chr 9:26,885,702...26,897,219
Ensembl chr 9:26,885,708...26,897,219
JBrowse link
G Il1a interleukin 1 alpha multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1A mRNA CTD PMID:27738319 NCBI chr 3:121,824,712...121,836,122
Ensembl chr 3:121,825,412...121,836,086
JBrowse link
G Il1b interleukin 1 beta multiple interactions
increases secretion
ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1B mRNA
Erlotinib Hydrochloride results in increased secretion of IL1B protein
CTD PMID:27738319 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Il1r1 interleukin 1 receptor type 1 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1R1 mRNA CTD PMID:27738319 NCBI chr 9:46,962,291...47,038,139
Ensembl chr 9:46,962,288...47,036,670
JBrowse link
G Il1r2 interleukin 1 receptor type 2 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1R2 mRNA CTD PMID:27738319 NCBI chr 9:46,840,646...46,881,241
Ensembl chr 9:46,840,992...46,881,264
JBrowse link
G Il1rap interleukin 1 receptor accessory protein multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of IL1RAP mRNA CTD PMID:27738319 NCBI chr11:77,456,648...77,593,208
Ensembl chr11:77,463,954...77,593,207
JBrowse link
G Il1rn interleukin 1 receptor antagonist multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IL1RN mRNA; [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased secretion of IL1RN protein CTD PMID:27738319 NCBI chr 3:1,449,778...1,468,624
Ensembl chr 3:1,452,644...1,468,614
JBrowse link
G Il2 interleukin 2 decreases secretion ISO Erlotinib Hydrochloride results in decreased secretion of IL2 protein CTD PMID:21195724 NCBI chr 2:123,847,150...123,851,854
Ensembl chr 2:123,847,150...123,851,854
JBrowse link
G Il25 interleukin 25 increases expression ISO
EXP
Erlotinib Hydrochloride results in increased expression of IL25 mRNA CTD PMID:24768708 NCBI chr15:33,594,852...33,599,692
Ensembl chr15:33,596,301...33,599,685
JBrowse link
G Il2ra interleukin 2 receptor subunit alpha decreases expression ISO Erlotinib Hydrochloride results in decreased expression of IL2RA protein CTD PMID:21195724 NCBI chr17:70,500,672...70,547,929
Ensembl chr17:70,499,083...70,548,071
JBrowse link
G Il6 interleukin 6 increases expression
increases secretion
multiple interactions
ISO
EXP
Erlotinib Hydrochloride results in increased expression of IL6 mRNA
Erlotinib Hydrochloride results in increased secretion of IL6 protein
Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; Erlotinib Hydrochloride inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein]; Interleukin 1 Receptor Antagonist Protein inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]
DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased expression of IL6 mRNA]; DDIT3 mutant form inhibits the reaction [Erlotinib Hydrochloride results in increased secretion of IL6 protein]
CTD PMID:24768708, PMID:27738319, PMID:30623574 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Irak1 interleukin-1 receptor-associated kinase 1 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased expression of IRAK1 mRNA CTD PMID:27738319 NCBI chr  X:156,716,469...156,726,367
Ensembl chr  X:156,716,604...156,725,977
JBrowse link
G Itgb1 integrin subunit beta 1 decreases expression EXP Erlotinib Hydrochloride results in decreased expression of ITGB1 mRNA CTD PMID:24768708 NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
JBrowse link
G Jak2 Janus kinase 2 decreases phosphorylation ISO Erlotinib Hydrochloride results in decreased phosphorylation of JAK2 protein CTD PMID:23894143 NCBI chr 1:247,398,667...247,457,521
Ensembl chr 1:247,398,598...247,458,509
JBrowse link
G Kcnh2 potassium voltage-gated channel subfamily H member 2 affects activity ISO Erlotinib Hydrochloride affects the activity of KCNH2 protein CTD PMID:23707608 NCBI chr 4:7,355,066...7,387,282
Ensembl chr 4:7,355,574...7,387,253
JBrowse link
G Kitlg KIT ligand multiple interactions ISO [gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of KITLG protein CTD PMID:24979617 NCBI chr 7:42,269,784...42,351,054
Ensembl chr 7:42,269,784...42,351,054
JBrowse link
G Kras KRAS proto-oncogene, GTPase increases response to substance ISO KRAS protein results in increased susceptibility to Erlotinib Hydrochloride CTD PMID:20705357 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G Map1lc3b microtubule-associated protein 1 light chain 3 beta multiple interactions ISO Erlotinib Hydrochloride promotes the reaction [betulinic acid results in increased expression of MAP1LC3B protein modified form] CTD PMID:30136359 NCBI chr19:53,635,449...53,643,970
Ensembl chr19:53,629,779...53,646,058
JBrowse link
G Mapk1 mitogen activated protein kinase 1 decreases phosphorylation
multiple interactions
ISO
EXP
Erlotinib Hydrochloride results in decreased phosphorylation of MAPK1 protein
Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK1 protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]
Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK1 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK1 protein]
CTD PMID:18787115, PMID:18980991, PMID:21195724, PMID:27427493, PMID:28101945 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 decreases phosphorylation
multiple interactions
ISO
EXP
Erlotinib Hydrochloride results in decreased phosphorylation of MAPK3 protein
Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased phosphorylation of MAPK3 protein]
Erlotinib Hydrochloride inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]
Erlotinib Hydrochloride inhibits the reaction [Alprenolol results in increased phosphorylation of MAPK3 protein]; Erlotinib Hydrochloride inhibits the reaction [carvedilol results in increased phosphorylation of MAPK3 protein]
CTD PMID:18787115, PMID:18980991, PMID:21195724, PMID:27427493, PMID:28101945 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases expression
multiple interactions
ISO Erlotinib Hydrochloride results in decreased expression of MCL1 protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased expression of MCL1 protein]
CTD PMID:25895606 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Met MET proto-oncogene, receptor tyrosine kinase multiple interactions
decreases phosphorylation
ISO [Erlotinib Hydrochloride co-treated with Dasatinib] results in decreased phosphorylation of MET protein
Erlotinib Hydrochloride results in decreased phosphorylation of MET protein
CTD PMID:21106725, PMID:23894143 NCBI chr 4:44,747,467...44,854,628
Ensembl chr 4:44,774,741...44,852,665
JBrowse link
G Micb MHC class I polypeptide-related sequence B increases expression ISO Erlotinib Hydrochloride results in increased expression of MICB protein CTD PMID:21951556 NCBI chr 1:79,754,587...79,772,092
Ensembl chr 1:79,754,587...79,772,092
JBrowse link
G Mmp14 matrix metallopeptidase 14 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MMP14 mRNA] CTD PMID:19661247 NCBI chr15:33,074,441...33,083,666
Ensembl chr15:33,074,441...33,083,655
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP2 mRNA CTD PMID:29274334 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of MMP9 mRNA CTD PMID:29274334 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Msmo1 methylsterol monooxygenase 1 decreases response to substance
multiple interactions
ISO MSMO1 protein results in decreased susceptibility to Erlotinib Hydrochloride
MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form]
CTD PMID:23125191 NCBI chr16:26,859,441...26,875,880
Ensembl chr16:26,859,397...26,875,973
JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation
multiple interactions
ISO Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of MTOR protein]
CTD PMID:21655094, PMID:25895606 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [Acrolein results in increased expression of MUC5AC mRNA] CTD PMID:18006877, PMID:19661247 NCBI chr 1:214,725,482...214,756,653 JBrowse link
G Myd88 MYD88, innate immune signal transduction adaptor multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of MYD88 mRNA CTD PMID:27738319 NCBI chr 8:128,022,512...128,027,462
Ensembl chr 8:128,022,473...128,026,841
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which affects the expression of NFKBIA mRNA CTD PMID:27738319 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nol10 nucleolar protein 10 decreases expression ISO Erlotinib Hydrochloride results in decreased expression of NOL10 mRNA CTD PMID:27720938 NCBI chr 6:42,656,661...42,745,099
Ensembl chr 6:42,656,616...42,745,098
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
decreases response to substance
increases expression
ISO Erlotinib Hydrochloride results in increased expression of and results in increased stability of NOX4 mRNA
NOX4 protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased expression of NOX4 protein
CTD PMID:23917044 NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
JBrowse link
G Nr1i2 nuclear receptor subfamily 1, group I, member 2 multiple interactions ISO Erlotinib Hydrochloride binds to and results in increased activity of NR1I2 protein CTD PMID:18839173 NCBI chr11:65,022,100...65,058,546
Ensembl chr11:65,022,100...65,058,545
JBrowse link
G Nr1i3 nuclear receptor subfamily 1, group I, member 3 affects localization ISO Erlotinib Hydrochloride affects the localization of NR1I3 protein mutant form CTD PMID:30364229 NCBI chr13:89,585,072...89,591,278
Ensembl chr13:89,586,283...89,591,277
JBrowse link
G Nsdhl NAD(P) dependent steroid dehydrogenase-like decreases response to substance ISO NSDHL protein results in decreased susceptibility to Erlotinib Hydrochloride CTD PMID:23125191 NCBI chr  X:152,933,118...152,964,399
Ensembl chr  X:152,933,069...152,964,390
JBrowse link
G Osm oncostatin M multiple interactions ISO [gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of OSM protein CTD PMID:24979617 NCBI chr14:84,457,487...84,469,426
Ensembl chr14:84,465,515...84,470,409
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases cleavage
multiple interactions
increases expression
ISO Erlotinib Hydrochloride results in increased cleavage of PARP1 protein
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; Harmine promotes the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]
CTD PMID:23125191, PMID:25895606, PMID:30171258 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pml PML nuclear body scaffold increases expression
decreases response to substance
increases localization
ISO Erlotinib Hydrochloride results in increased expression of PML protein
PML protein results in decreased susceptibility to Erlotinib Hydrochloride
Erlotinib Hydrochloride results in increased localization of PML protein
CTD PMID:23440206 NCBI chr 8:63,002,515...63,034,310
Ensembl chr 8:63,004,870...63,034,226
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of PTGS2 mRNA CTD PMID:27738319 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Ptpn9 protein tyrosine phosphatase, non-receptor type 9 decreases expression
decreases response to substance
ISO Erlotinib Hydrochloride results in decreased expression of PTPN9 protein
PTPN9 mutant form results in decreased susceptibility to Erlotinib Hydrochloride
CTD PMID:23894143 NCBI chr 8:61,658,851...61,739,458
Ensembl chr 8:61,659,445...61,739,434
JBrowse link
G Rad50 RAD50 double strand break repair protein multiple interactions ISO [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD50 protein CTD PMID:23548265 NCBI chr10:39,002,130...39,054,042
Ensembl chr10:39,001,498...39,054,142
JBrowse link
G Rad51 RAD51 recombinase multiple interactions ISO [Erlotinib Hydrochloride results in decreased activity of EGFR protein] which results in decreased expression of RAD51 protein CTD PMID:23548265 NCBI chr 3:110,918,240...110,942,920
Ensembl chr 3:110,918,243...110,942,917
JBrowse link
G Raf1 Raf-1 proto-oncogene, serine/threonine kinase decreases phosphorylation ISO Erlotinib Hydrochloride results in decreased phosphorylation of RAF1 protein CTD PMID:21195724 NCBI chr 4:147,532,040...147,592,769
Ensembl chr 4:147,532,042...147,592,699
JBrowse link
G Rb1 RB transcriptional corepressor 1 decreases phosphorylation
multiple interactions
decreases expression
ISO Erlotinib Hydrochloride results in decreased phosphorylation of RB1 protein
betulinic acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of RB1 protein modified form]; Erlotinib Hydrochloride promotes the reaction [betulinic acid results in decreased expression of RB1 protein modified form]
CTD PMID:21195724, PMID:30136359 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [Particulate Matter analog results in increased acetylation of RELA protein] CTD PMID:28101945 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rps6 ribosomal protein S6 decreases phosphorylation
decreases expression
multiple interactions
ISO Erlotinib Hydrochloride results in decreased phosphorylation of RPS6 protein
Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form
MSMO1 protein inhibits the reaction [Erlotinib Hydrochloride results in decreased expression of RPS6 protein modified form]
CTD PMID:23125191, PMID:23440206 NCBI chr 5:105,197,821...105,200,681
Ensembl chr 5:105,197,857...105,200,148
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation
multiple interactions
ISO Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein
resveratrol promotes the reaction [Erlotinib Hydrochloride results in decreased phosphorylation of RPS6KB1 protein]
CTD PMID:21655094, PMID:25895606 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Selenbp1 selenium binding protein 1 decreases expression ISO Erlotinib Hydrochloride results in decreased expression of SELENBP1 mRNA CTD PMID:27720938 NCBI chr 2:196,105,592...196,146,474
Ensembl chr 2:196,105,569...196,113,149
JBrowse link
G Siah2 siah E3 ubiquitin protein ligase 2 decreases expression ISO Erlotinib Hydrochloride results in decreased expression of SIAH2 mRNA CTD PMID:27720938 NCBI chr 2:148,874,151...148,891,900
Ensembl chr 2:148,874,151...148,891,900
JBrowse link
G Snai1 snail family transcriptional repressor 1 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI1 mRNA CTD PMID:29274334 NCBI chr 3:164,274,710...164,279,199
Ensembl chr 3:164,274,710...164,279,378
JBrowse link
G Snai2 snail family transcriptional repressor 2 multiple interactions ISO [Erlotinib Hydrochloride co-treated with Arsenic Trioxide] results in decreased expression of SNAI2 mRNA CTD PMID:29274334 NCBI chr11:90,404,421...90,406,730
Ensembl chr11:90,403,333...90,406,797
JBrowse link
G Socs3 suppressor of cytokine signaling 3 increases expression EXP Erlotinib Hydrochloride results in increased expression of SOCS3 mRNA CTD PMID:24768708 NCBI chr10:106,973,863...106,976,969
Ensembl chr10:106,975,178...106,976,040
JBrowse link
G Sox9 SRY-box transcription factor 9 multiple interactions
decreases expression
ISO Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 mRNA]; Erlotinib Hydrochloride inhibits the reaction [EGFR protein mutant form results in increased expression of SOX9 protein]
Erlotinib Hydrochloride results in decreased expression of SOX9 protein
CTD PMID:26455392 NCBI chr10:101,288,528...101,294,030
Ensembl chr10:101,288,489...101,293,379
JBrowse link
G Sqstm1 sequestosome 1 increases expression ISO Erlotinib Hydrochloride results in increased expression of SQSTM1 protein CTD PMID:30136359 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase decreases phosphorylation ISO Erlotinib Hydrochloride results in decreased phosphorylation of SRC protein CTD PMID:23894143 NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
JBrowse link
G Stat3 signal transducer and activator of transcription 3 increases phosphorylation
decreases expression
increases response to substance
decreases response to substance
multiple interactions
ISO Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein
Erlotinib Hydrochloride results in decreased expression of STAT3 protein modified form
STAT3 mutant form results in increased susceptibility to Erlotinib Hydrochloride
STAT3 mRNA results in decreased susceptibility to Erlotinib Hydrochloride
[betulinic acid co-treated with Erlotinib Hydrochloride] results in decreased expression of STAT3 protein modified form; [Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]] which results in increased susceptibility to Erlotinib Hydrochloride; Niclosamide inhibits the reaction [Erlotinib Hydrochloride results in increased phosphorylation of STAT3 protein]
CTD PMID:23125191, PMID:23894143, PMID:30136359 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Tent5c terminal nucleotidyltransferase 5C decreases expression ISO Erlotinib Hydrochloride results in decreased expression of TENT5C mRNA CTD PMID:27720938 NCBI chr 2:202,797,766...202,816,562
Ensembl chr 2:202,798,198...202,816,562
JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] CTD PMID:21499124, PMID:21951556 NCBI chr17:24,653,342...24,670,457
Ensembl chr17:24,654,902...24,670,457
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [TGFA protein results in decreased susceptibility to crizotinib] CTD PMID:22553343 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions ISO Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to Cisplatin]]; Erlotinib Hydrochloride inhibits the reaction [EGF promotes the reaction [TGFB1 results in decreased susceptibility to gemcitabine]] CTD PMID:21613822 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tmed2 transmembrane p24 trafficking protein 2 decreases response to substance ISO TMED2 mRNA results in decreased susceptibility to Erlotinib Hydrochloride CTD PMID:23125191 NCBI chr12:37,471,259...37,480,344
Ensembl chr12:37,471,260...37,480,297
JBrowse link
G Tnfsf8 TNF superfamily member 8 multiple interactions ISO [gemcitabine co-treated with Erlotinib Hydrochloride] affects the expression of TNFSF8 protein CTD PMID:24979617 NCBI chr 5:79,664,779...79,691,547
Ensembl chr 5:79,664,765...79,691,258
JBrowse link
G Tollip toll interacting protein multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of TOLLIP mRNA CTD PMID:27738319 NCBI chr 1:214,823,993...214,844,861
Ensembl chr 1:214,823,978...214,844,858
JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression
ISO Erlotinib Hydrochloride promotes the reaction [Arsenic Trioxide results in increased expression of TP53 mRNA]; Erlotinib Hydrochloride promotes the reaction [Resveratrol results in increased expression of TP53 protein]; Resveratrol promotes the reaction [Erlotinib Hydrochloride results in increased expression of TP53 protein] CTD PMID:25895606, PMID:29274334 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Traf6 TNF receptor associated factor 6 multiple interactions ISO [Erlotinib Hydrochloride results in decreased susceptibility to Erlotinib Hydrochloride] which results in increased expression of TRAF6 mRNA CTD PMID:27738319 NCBI chr 3:91,252,829...91,271,607
Ensembl chr 3:91,252,829...91,271,607
JBrowse link
G Twist1 twist family bHLH transcription factor 1 increases expression
decreases response to substance
multiple interactions
ISO Erlotinib Hydrochloride results in increased expression of TWIST1 protein
TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [Erlotinib Hydrochloride results in increased cleavage of PARP1 protein]
[TWIST1 protein results in decreased susceptibility to Erlotinib Hydrochloride] which results in decreased cleavage of CASP3 protein
CTD PMID:30171258 NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
JBrowse link
G Tyms thymidylate synthetase decreases expression
multiple interactions
ISO Erlotinib Hydrochloride results in decreased expression of TYMS protein
betulinic acid promotes the reaction [Erlotinib Hydrochloride results in decreased expression of TYMS protein]; Erlotinib Hydrochloride promotes the reaction [betulinic acid results in decreased expression of TYMS protein]
CTD PMID:30136359 NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
JBrowse link
G Ulbp1 UL16 binding protein 1 increases expression
multiple interactions
ISO Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA; Erlotinib Hydrochloride results in increased expression of ULBP1 protein
Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Erlotinib Hydrochloride results in increased expression of ULBP1 mRNA]
CTD PMID:21499124, PMID:21951556 NCBI chr 1:1,181,301...1,200,526
Ensembl chr 1:1,180,932...1,220,916
JBrowse link
G Xbp1 X-box binding protein 1 increases expression EXP Erlotinib Hydrochloride results in increased expression of XBP1 protein modified form CTD PMID:24768708 NCBI chr14:85,753,736...85,758,820
Ensembl chr14:85,753,760...85,758,145
JBrowse link
gefitinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcb11 ATP binding cassette subfamily B member 11 decreases activity ISO gefitinib results in decreased activity of ABCB11 protein CTD PMID:20829430, PMID:23956101 NCBI chr 3:55,480,024...55,587,946
Ensembl chr 3:55,480,024...55,587,946
JBrowse link
G Abcg2 ATP binding cassette subfamily G member 2 multiple interactions ISO [[gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; gefitinib inhibits the reaction [ABCG2 protein results in decreased susceptibility to Doxorubicin] CTD PMID:17938326 NCBI chr 4:88,765,441...88,890,268
Ensembl chr 4:88,832,178...88,890,621
JBrowse link
G Adora1 adenosine A1 receptor decreases expression ISO gefitinib results in decreased expression of ADORA1 mRNA CTD PMID:16685379 NCBI chr13:51,042,111...51,076,913
Ensembl chr13:51,042,248...51,076,852
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions
decreases expression
ISO
EXP
Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of AKT1 protein]
Gefitinib results in decreased expression of AKT1 mRNA
Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of AKT1 protein]
CTD PMID:17805209, PMID:19233551, PMID:23255615, PMID:23948867, PMID:24568969, PMID:27087131, PMID:28942004, PMID:30993382, PMID:32370496 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Ar androgen receptor multiple interactions ISO Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]] CTD PMID:29383186 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Areg amphiregulin affects response to substance
multiple interactions
decreases response to substance
ISO AREG protein affects the susceptibility to gefitinib
Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased expression of AREG mRNA]; Gefitinib inhibits the reaction [Irinotecan results in increased expression of AREG mRNA]
AREG protein results in decreased susceptibility to gefitinib
CTD PMID:15496427, PMID:15723263, PMID:16230376, PMID:18980991, PMID:21258428 NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
JBrowse link
G Atg5 autophagy related 5 increases expression ISO gefitinib results in increased expression of ATG5 protein CTD PMID:21655094 NCBI chr20:49,301,783...49,393,147
Ensembl chr20:49,318,308...49,393,140
JBrowse link
G Atg7 autophagy related 7 increases expression ISO gefitinib results in increased expression of ATG7 protein CTD PMID:21655094 NCBI chr 4:146,570,113...146,777,093
Ensembl chr 4:146,598,413...146,777,124
JBrowse link
G Aurka aurora kinase A decreases response to substance
multiple interactions
ISO AURKA results in decreased susceptibility to gefitinib
[AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to Gefitinib; [TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib
CTD PMID:21216229 NCBI chr 3:170,364,177...170,380,278
Ensembl chr 3:170,364,181...170,378,210
JBrowse link
G Aven apoptosis and caspase activation inhibitor affects response to substance ISO AVEN protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 3:103,980,612...104,117,193
Ensembl chr 3:104,042,168...104,117,192
JBrowse link
G Bax BCL2 associated X, apoptosis regulator increases expression EXP Gefitinib results in increased expression of BAX mRNA; Gefitinib results in increased expression of BAX protein CTD PMID:32370496 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2l11 BCL2 like 11 increases response to substance ISO BCL2L11 protein results in increased susceptibility to gefitinib CTD PMID:20237869 NCBI chr 3:120,726,906...120,764,192
Ensembl chr 3:120,726,906...120,764,192
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 increases expression
decreases expression
multiple interactions
ISO gefitinib results in increased expression of BIRC5 protein
gefitinib results in decreased expression of BIRC5 protein
leptomycin B promotes the reaction [Gefitinib results in decreased expression of BIRC5 protein]; tyrphostin AG 1024 inhibits the reaction [Gefitinib results in increased expression of BIRC5 protein]
CTD PMID:17473213, PMID:28942004 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Bnip3 BCL2 interacting protein 3 multiple interactions ISO gefitinib inhibits the reaction [bafilomycin A1 results in increased expression of BNIP3 protein] CTD PMID:25981168 NCBI chr 1:211,248,098...211,265,282
Ensembl chr 1:211,248,098...211,265,282
JBrowse link
G Casp3 caspase 3 increases expression
multiple interactions
EXP
ISO
gefitinib results in increased expression of CASP3 mRNA; gefitinib results in increased expression of CASP3 protein
EGFR gene mutant form promotes the reaction [gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; gefitinib results in increased cleavage of and results in increased activity of CASP3 protein
CTD PMID:23523951, PMID:27084042, PMID:27639429 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Casp8 caspase 8 increases cleavage ISO Gefitinib results in increased cleavage of CASP8 protein CTD PMID:31168030 NCBI chr 9:65,614,142...65,662,624
Ensembl chr 9:65,614,142...65,662,106
JBrowse link
G Cav1 caveolin 1 increases expression ISO gefitinib results in increased expression of CAV1 mRNA; gefitinib results in increased expression of CAV1 protein CTD PMID:19288272 NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
JBrowse link
G Ccnd1 cyclin D1 decreases expression
multiple interactions
ISO gefitinib results in decreased expression of CCND1 protein
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of CCND1 protein]
CTD PMID:16740687, PMID:17513607, PMID:23948867 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccnd3 cyclin D3 decreases expression ISO gefitinib results in decreased expression of CCND3 protein CTD PMID:16740687 NCBI chr 9:15,404,816...15,410,905
Ensembl chr 9:15,404,822...15,410,943
JBrowse link
G Cd14 CD14 molecule multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]]; [gefitinib promotes the reaction arsenic trioxide] which results in increased expression of CD14 mRNA; gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]; SB 203580 inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of CD14 protein]] CTD PMID:20226526 NCBI chr18:29,560,341...29,562,290
Ensembl chr18:29,560,365...29,562,153
JBrowse link
G Cdk6 cyclin-dependent kinase 6 multiple interactions
decreases expression
ISO betulinic acid promotes the reaction [Gefitinib results in decreased expression of CDK6 protein] CTD PMID:30136359 NCBI chr 4:27,781,728...27,969,653
Ensembl chr 4:27,785,647...27,966,398
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A increases expression
multiple interactions
decreases expression
ISO gefitinib results in increased expression of CDKN1A protein
leptomycin B inhibits the reaction [gefitinib results in decreased expression of CDKN1A protein]
CTD PMID:17513607, PMID:28942004 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cdkn1b cyclin-dependent kinase inhibitor 1B multiple interactions
increases expression
decreases expression
ISO gefitinib promotes the reaction [[zoledronic acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of CDKN1B protein]
gefitinib results in increased expression of CDKN1B protein
gefitinib results in decreased expression of CDKN1B
CTD PMID:14679152, PMID:16322342, PMID:16740687, PMID:17513607 NCBI chr 4:168,689,043...168,694,159
Ensembl chr 4:168,689,163...168,693,964
JBrowse link
G Cdkn2b cyclin-dependent kinase inhibitor 2B increases expression ISO gefitinib results in increased expression of CDKN2B mRNA; gefitinib results in increased expression of CDKN2B protein CTD PMID:17513607 NCBI chr 5:107,834,353...107,857,428
Ensembl chr 5:107,845,951...107,858,104
JBrowse link
G Cert1 ceramide transporter 1 affects response to substance ISO CERT1 protein affects the susceptibility to Gefitinib CTD PMID:15496427 NCBI chr 2:27,365,145...27,469,797
Ensembl chr 2:27,365,148...27,469,779
JBrowse link
G Cgrrf1 cell growth regulator with ring finger domain 1 increases expression ISO gefitinib results in increased expression of CGRRF1 mRNA CTD PMID:16685379 NCBI chr15:23,619,176...23,639,622
Ensembl chr15:23,619,123...23,639,628
JBrowse link
G Cldn2 claudin 2 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of CLDN2 mRNA CTD PMID:20935109 NCBI chr  X:111,122,552...111,133,188
Ensembl chr  X:111,122,552...111,137,769
JBrowse link
G Coro1c coronin 1C affects response to substance ISO CORO1C protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr12:48,481,741...48,554,054
Ensembl chr12:48,481,750...48,554,052
JBrowse link
G Cycs cytochrome c, somatic affects localization ISO gefitinib affects the localization of CYCS protein CTD PMID:23523951 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Cyp1a1 cytochrome P450, family 1, subfamily a, polypeptide 1 increases response to substance
increases expression
ISO
EXP
CYP1A1 protein results in increased susceptibility to gefitinib
Gefitinib results in increased expression of CYP1A1 mRNA
CTD PMID:28652202, PMID:32370496 NCBI chr 8:62,472,087...62,478,122
Ensembl chr 8:62,472,095...62,478,147
JBrowse link
G Cyp2d4 cytochrome P450, family 2, subfamily d, polypeptide 4 affects metabolic processing ISO CYP2D6 protein affects the metabolism of gefitinib CTD PMID:15788367 NCBI chr 7:123,599,264...123,608,436
Ensembl chr 7:123,599,266...123,608,436
JBrowse link
G Cyp2f4 cytochrome P450, family 2, subfamily f, polypeptide 4 decreases expression ISO gefitinib results in decreased expression of CYP2F1 mRNA CTD PMID:16685379 NCBI chr 1:83,933,974...83,947,804
Ensembl chr 1:83,933,942...83,947,821
JBrowse link
G Cyp3a9 cytochrome P450, family 3, subfamily a, polypeptide 9 affects metabolic processing ISO CYP3A5 protein affects the metabolism of gefitinib CTD PMID:15788367 NCBI chr12:19,074,288...19,114,491
Ensembl chr12:19,074,583...19,114,399
JBrowse link
G Dusp3 dual specificity phosphatase 3 affects response to substance ISO DUSP3 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr10:89,904,578...89,918,296
Ensembl chr10:89,904,560...89,918,427
JBrowse link
G Dusp9 dual specificity phosphatase 9 decreases expression ISO gefitinib results in decreased expression of DUSP9 mRNA CTD PMID:16685379 NCBI chr  X:157,168,143...157,172,068
Ensembl chr  X:157,168,144...157,172,068
JBrowse link
G E2f1 E2F transcription factor 1 decreases expression ISO gefitinib results in decreased expression of E2F1 mRNA; gefitinib results in decreased expression of E2F1 protein CTD PMID:17094457, PMID:18347146 NCBI chr 3:150,062,895...150,073,721
Ensembl chr 3:150,047,826...150,073,721
JBrowse link
G Ednrb endothelin receptor type B multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA] CTD PMID:18424623 NCBI chr15:88,004,775...88,036,354
Ensembl chr15:88,006,977...88,036,354
JBrowse link
G Egf epidermal growth factor multiple interactions ISO Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [Hydrocortisone inhibits the reaction [EGF protein results in increased abundance of Dinoprostone]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Gefitinib promotes the reaction [Resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; Resveratrol promotes the reaction [Gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]
gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]
CTD PMID:15841081, PMID:16243822, PMID:17805209, PMID:17898861, PMID:18927496, PMID:19233551, PMID:19318490, PMID:20088784, PMID:21787763, PMID:23127547, PMID:27087131 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor decreases response to substance
decreases activity
multiple interactions
decreases phosphorylation
decreases expression
increases response to substance
affects response to substance
ISO
EXP
EGFR gene mutant form results in decreased susceptibility to Gefitinib; EGFR protein mutant form results in decreased susceptibility to Gefitinib
Gefitinib results in decreased activity of EGFR protein
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]
gefitinib results in decreased activity of EGFR protein
Gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased phosphorylation of EGFR protein
gefitinib results in decreased expression of EGFR protein modified form
[Gefitinib results in decreased activity of EGFR protein] which results in increased susceptibility to naphthalene; Gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [Folic Acid results in increased phosphorylation of EGFR protein]; Gefitinib results in decreased phosphorylation of and results in decreased activity of EGFR protein
Gefitinib results in decreased expression of EGFR protein modified form
[[Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein] which results in decreased export of Doxorubicin; [Gefitinib co-treated with betulin] results in decreased expression of and results in decreased phosphorylation of EGFR protein; [Gefitinib co-treated with Oxaliplatin] results in decreased phosphorylation of EGFR protein; [Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]] which results in decreased activity of EGFR protein; [Gefitinib results in decreased activity of EGFR protein] which affects the localization of ABCG2 protein; [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to Gefitinib; betulinic acid promotes the reaction [Gefitinib results in decreased expression of EGFR protein modified form]; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein]; EGFR gene mutant form promotes the reaction [Gefitinib results in increased cleavage of and results in increased activity of CASP3 protein]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to AR protein]]; Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [EGF results in increased phosphorylation of EGFR protein]; Gefitinib inhibits the reaction [EGFR protein results in decreased susceptibility to Docetaxel]; Gefitinib inhibits the reaction [gemcitabine results in increased phosphorylation of and results in increased degradation of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan metabolite results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Irinotecan results in increased phosphorylation of and results in increased activity of EGFR protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of EGFR protein]; Gefitinib promotes the reaction [EGF protein binds to EGFR protein]; Gefitinib promotes the reaction [EGFR protein binds to EGFR protein]; Gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to EGFR protein]; Gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]; Gefitinib results in decreased expression of and results in decreased phosphorylation of EGFR protein; KRAS protein affects the reaction [EGFR protein affects the susceptibility to Gefitinib]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]
EGFR gene mutant form results in increased susceptibility to gefitinib; EGFR gene polymorphism results in increased susceptibility to gefitinib; EGFR protein mutant form results in increased susceptibility to gefitinib
EGFR gene mutant form affects the susceptibility to Gefitinib; EGFR protein affects the susceptibility to Gefitinib; EGFR protein mutant form affects the susceptibility to Gefitinib
CTD PMID:13680161, PMID:14679152, PMID:15660382, PMID:15723263, PMID:15841081, PMID:15976335, PMID:16115929, PMID:16243822, PMID:16740687, PMID:16824645, PMID:17145836, PMID:17146438, PMID:17236550, PMID:17270025, PMID:17290066, PMID:17473213, PMID:17898861, PMID:17938326, PMID:18271929, PMID:18375820, PMID:18625569, PMID:18771084, PMID:18927496, PMID:19288272, PMID:19318490, PMID:20549698, PMID:20846305, PMID:20935109, PMID:21258428, PMID:21478906, PMID:21544845, PMID:21787763, PMID:23255615, PMID:23948867, PMID:24888374, PMID:27087131, PMID:27447558, PMID:27639429, PMID:28739874, PMID:28942004, PMID:29228391, PMID:29383186, PMID:30136359, PMID:30237564, PMID:30549224, PMID:30993382, PMID:32370496 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Epor erythropoietin receptor increases expression ISO gefitinib results in increased expression of EPOR mRNA CTD PMID:16685379 NCBI chr 8:22,969,737...22,974,468
Ensembl chr 8:22,969,745...22,974,321
JBrowse link
G Eps15 epidermal growth factor receptor pathway substrate 15 increases expression ISO gefitinib results in increased expression of EPS15 mRNA CTD PMID:16685379 NCBI chr 5:128,923,809...129,022,268
Ensembl chr 5:128,923,934...129,022,054
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions
decreases phosphorylation
ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of ERBB2 protein]; gefitinib results in decreased activity of [EGFR protein binds to ERBB2 protein]
gefitinib results in decreased phosphorylation of ERBB2 protein
CTD PMID:16243822, PMID:17898861 NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
JBrowse link
G Ercc1 ERCC excision repair 1, endonuclease non-catalytic subunit multiple interactions
affects response to substance
ISO ERCC1 gene polymorphism affects the susceptibility to [gefitinib co-treated with Cisplatin]
ERCC1 gene polymorphism affects the susceptibility to gefitinib
CTD PMID:21264830 NCBI chr 1:80,256,973...80,268,198
Ensembl chr 1:80,256,973...80,268,198
JBrowse link
G Esr1 estrogen receptor 1 decreases phosphorylation ISO gefitinib results in decreased phosphorylation of ESR1 protein CTD PMID:16261397 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G Esr2 estrogen receptor 2 increases expression
multiple interactions
ISO gefitinib results in increased expression of ESR2 protein
Gefitinib inhibits the reaction [bisphenol A promotes the reaction [EGFR protein binds to ESR2 protein]]
CTD PMID:20005069, PMID:29383186 NCBI chr 6:99,163,953...99,214,711
Ensembl chr 6:99,164,357...99,214,251
JBrowse link
G Faslg Fas ligand multiple interactions
increases response to substance
ISO benzyloxycarbonyl-valyl-alanyl-aspartyl-fluoromethane inhibits the reaction [Gefitinib results in increased susceptibility to FASLG protein] CTD PMID:31168030 NCBI chr13:79,696,811...79,717,581
Ensembl chr13:79,698,445...79,705,705
JBrowse link
G Fgf6 fibroblast growth factor 6 increases expression ISO gefitinib results in increased expression of FGF6 mRNA CTD PMID:16685379 NCBI chr 4:159,563,798...159,572,333
Ensembl chr 4:159,563,798...159,572,333
JBrowse link
G Foxf1 forkhead box F1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA] CTD PMID:18424623 NCBI chr19:53,012,306...53,016,100
Ensembl chr19:53,012,332...53,016,086
JBrowse link
G Foxo3 forkhead box O3 increases response to substance
increases expression
multiple interactions
ISO
EXP
FOXO3 protein results in increased susceptibility to gefitinib
Gefitinib results in increased expression of FOXO3 mRNA; Gefitinib results in increased expression of FOXO3 protein; Gefitinib results in increased expression of FOXO3 protein modified form
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of FOXO3 mRNA]
gefitinib results in decreased phosphorylation of and affects the localization of FOXO3 protein
CTD PMID:18089711, PMID:32370496 NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
JBrowse link
G Gadd45a growth arrest and DNA-damage-inducible, alpha increases expression ISO gefitinib results in increased expression of GADD45A mRNA CTD PMID:16685379 NCBI chr 4:97,782,512...97,784,814
Ensembl chr 4:97,782,512...97,784,842
JBrowse link
G Gadd45g growth arrest and DNA-damage-inducible, gamma decreases expression ISO gefitinib results in decreased expression of GADD45G mRNA CTD PMID:16685379 NCBI chr17:13,391,474...13,393,219
Ensembl chr17:13,391,467...13,393,243
JBrowse link
G Gars glycyl-tRNA synthetase increases expression ISO Gefitinib results in increased expression of GARS1 mRNA CTD PMID:16685379 NCBI chr 4:85,235,122...85,276,085
Ensembl chr 4:85,235,172...85,276,044
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit affects response to substance ISO GCLC protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gfap glial fibrillary acidic protein multiple interactions EXP gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]] CTD PMID:29228391 NCBI chr10:90,990,762...90,999,435
Ensembl chr10:90,990,762...90,999,506
JBrowse link
G Gnb2 G protein subunit beta 2 decreases expression ISO gefitinib results in decreased expression of GNB2 mRNA CTD PMID:16685379 NCBI chr12:22,229,079...22,234,096
Ensembl chr12:22,229,079...22,234,096
JBrowse link
G Gnmt glycine N-methyltransferase multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of GNMT mRNA CTD PMID:20935109 NCBI chr 9:16,565,274...16,568,626
Ensembl chr 9:16,565,225...16,568,627
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO Gefitinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Gsk3b glycogen synthase kinase 3 beta decreases expression ISO Gefitinib results in decreased expression of GSK3B protein modified form CTD PMID:30136359 NCBI chr11:65,060,884...65,208,842
Ensembl chr11:65,066,235...65,209,268
JBrowse link
G Gucy2d guanylate cyclase 2D, retinal decreases expression ISO gefitinib results in decreased expression of GUCY2D mRNA CTD PMID:16685379 NCBI chr10:55,835,695...55,851,235
Ensembl chr10:55,835,695...55,851,235
JBrowse link
G Havcr1 hepatitis A virus cellular receptor 1 multiple interactions ISO Gefitinib promotes the reaction [Folic Acid results in increased expression of HAVCR1 protein] CTD PMID:23255615 NCBI chr10:31,813,819...31,860,934
Ensembl chr10:31,813,814...31,848,379
JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions ISO
EXP
gefitinib inhibits the reaction [irinotecan metabolite results in increased expression of HBEGF mRNA]; gefitinib inhibits the reaction [irinotecan results in increased expression of HBEGF mRNA]
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased expression of GFAP protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased phosphorylation of and results in decreased activity of EGFR protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in decreased secretion of HBEGF protein]]; gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]
CTD PMID:15723263, PMID:29228391 NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
JBrowse link
G Hif1a hypoxia inducible factor 1 subunit alpha multiple interactions ISO gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of HIF1A protein] CTD PMID:21544845 NCBI chr 6:96,810,868...96,856,303
Ensembl chr 6:96,810,907...96,856,052
JBrowse link
G Hmox1 heme oxygenase 1 increases expression EXP gefitinib results in increased expression of HMOX1 mRNA; gefitinib results in increased expression of HMOX1 protein CTD PMID:27084042 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Igf1r insulin-like growth factor 1 receptor multiple interactions
increases phosphorylation
ISO gefitinib promotes the reaction [IGF1R protein binds to EGFR protein]; tyrphostin AG 1024 inhibits the reaction [gefitinib results in increased phosphorylation of IGF1R protein] CTD PMID:17473213 NCBI chr 1:128,924,921...129,213,816
Ensembl chr 1:128,924,966...129,206,516
JBrowse link
G Il1b interleukin 1 beta multiple interactions ISO gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of IL1B protein] CTD PMID:23948867 NCBI chr 3:121,876,256...121,882,637
Ensembl chr 3:121,876,263...121,882,726
JBrowse link
G Itgam integrin subunit alpha M multiple interactions ISO 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein]]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM mRNA]; gefitinib promotes the reaction [arsenic trioxide results in increased expression of ITGAM protein] CTD PMID:20226526 NCBI chr 1:199,495,312...199,545,738
Ensembl chr 1:199,495,298...199,623,960
JBrowse link
G Itgav integrin subunit alpha V multiple interactions ISO gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA] CTD PMID:15841081 NCBI chr 3:71,113,269...71,205,958
Ensembl chr 3:71,114,100...71,202,411
JBrowse link
G Itgb1 integrin subunit beta 1 multiple interactions ISO [ITGB1 protein results in increased activity of EGFR protein] which results in decreased susceptibility to gefitinib CTD PMID:21478906 NCBI chr19:61,677,512...61,725,537
Ensembl chr19:61,677,542...61,725,535
JBrowse link
G Kdr kinase insert domain receptor multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA] CTD PMID:18424623 NCBI chr14:34,727,677...34,787,127
Ensembl chr14:34,727,623...34,787,183
JBrowse link
G Keap1 Kelch-like ECH-associated protein 1 increases expression ISO gefitinib results in increased expression of KEAP1 mRNA CTD PMID:27639429 NCBI chr 8:22,250,518...22,259,868
Ensembl chr 8:22,250,518...22,259,779
JBrowse link
G Kras KRAS proto-oncogene, GTPase affects response to substance
decreases response to substance
multiple interactions
ISO KRAS protein mutant form affects the susceptibility to gefitinib
KRAS protein results in decreased susceptibility to gefitinib
KRAS protein affects the reaction [EGFR protein affects the susceptibility to gefitinib]
CTD PMID:17270025, PMID:28739874 NCBI chr 4:179,482,562...179,515,483
Ensembl chr 4:179,486,105...179,515,558
JBrowse link
G Lcn2 lipocalin 2 multiple interactions ISO Gefitinib promotes the reaction [Folic Acid results in increased expression of LCN2 protein] CTD PMID:23255615 NCBI chr 3:11,414,189...11,417,534
Ensembl chr 3:11,414,186...11,417,546
JBrowse link
G Lepr leptin receptor decreases expression ISO gefitinib results in decreased expression of LEPR mRNA CTD PMID:16685379 NCBI chr 5:120,503,475...120,682,281
Ensembl chr 5:120,564,645...120,682,221
JBrowse link
G Lgals9 galectin 9 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of LGALS9 mRNA CTD PMID:20935109 NCBI chr10:64,737,022...64,760,195
Ensembl chr10:64,737,022...64,760,201
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
increases phosphorylation
decreases phosphorylation
decreases expression
ISO
EXP
Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK1]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK1 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK1 protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK1 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK1 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK1 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK1 protein]
gefitinib results in increased phosphorylation of MAPK1 protein
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK1 protein]
gefitinib results in decreased expression of MAPK1 protein modified form
CTD PMID:15660382, PMID:16322342, PMID:17145836, PMID:17805209, PMID:17898861, PMID:18927496, PMID:19233551, PMID:19288272, PMID:19318490, PMID:19380191, PMID:20088784, PMID:21258428, PMID:21544845, PMID:21787763, PMID:24568969, PMID:27087131, PMID:28942004, PMID:29383186, PMID:30993382 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
increases phosphorylation
decreases expression
decreases phosphorylation
ISO
EXP
Gefitinib affects the reaction [ON123300 results in decreased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [[Promegestone co-treated with AREG protein] results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Dinoprostone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF affects the localization of MAPK3]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [EGF results in increased activity of MAPK3 protein]; Gefitinib inhibits the reaction [Promegestone results in increased phosphorylation of MAPK3 protein]; Gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased phosphorylation of MAPK3 protein]; Gefitinib promotes the reaction [[Zoledronic Acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased phosphorylation of MAPK3 protein]; Gefitinib results in decreased expression of and affects the phosphorylation of MAPK3 protein; leptomycin B inhibits the reaction [Gefitinib results in decreased phosphorylation of MAPK3 protein]
gefitinib inhibits the reaction [Diethylnitrosamine results in increased phosphorylation of MAPK3 protein]
gefitinib results in increased phosphorylation of MAPK3 protein
gefitinib results in decreased expression of MAPK3 protein modified form
CTD PMID:15660382, PMID:16322342, PMID:17145836, PMID:17805209, PMID:17898861, PMID:18927496, PMID:19233551, PMID:19288272, PMID:19318490, PMID:19380191, PMID:20088784, PMID:21258428, PMID:21544845, PMID:21787763, PMID:24568969, PMID:27087131, PMID:28942004, PMID:29383186, PMID:30993382 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 increases phosphorylation ISO gefitinib results in increased phosphorylation of MAPK8 protein CTD PMID:20846305 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Marveld1 MARVEL domain containing 1 decreases response to substance ISO MARVELD1 protein results in decreased susceptibility to Gefitinib CTD PMID:27447558 NCBI chr 1:261,389,804...261,393,736
Ensembl chr 1:261,389,804...261,393,736
JBrowse link
G Mdk midkine multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA] CTD PMID:18424623 NCBI chr 3:80,841,003...80,843,895
Ensembl chr 3:80,841,005...80,842,916
JBrowse link
G Micb MHC class I polypeptide-related sequence B increases expression ISO Gefitinib results in increased expression of MICB protein CTD PMID:21951556 NCBI chr 1:79,754,587...79,772,092
Ensembl chr 1:79,754,587...79,772,092
JBrowse link
G Mill1 MHC I like leukocyte 1 increases expression ISO Gefitinib results in increased expression of MICA protein CTD PMID:21951556 NCBI chr 1:79,631,266...79,657,943
Ensembl chr 1:79,631,668...79,657,941
JBrowse link
G Mki67 marker of proliferation Ki-67 multiple interactions ISO [Gefitinib co-treated with betulin] results in decreased expression of MKI67 protein CTD PMID:27447558 NCBI chr 1:207,993,895...208,020,454
Ensembl chr 1:207,993,895...208,020,454
JBrowse link
G Mlh1 mutL homolog 1 decreases expression ISO gefitinib results in decreased expression of MLH1 mRNA CTD PMID:16685379 NCBI chr 8:119,486,655...119,523,716
Ensembl chr 8:119,486,691...119,523,964
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO
EXP
gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA]
gefitinib inhibits the reaction [HBEGF protein inhibits the reaction [sodium arsenite results in increased expression of and results in increased secretion of and results in increased activity of MMP9 protein]]
gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 protein]; gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of MMP9 mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of MMP9 mRNA]]
CTD PMID:15841081, PMID:23127547, PMID:27087131, PMID:29228391 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mr1 major histocompatibility complex, class I-related affects expression ISO gefitinib affects the expression of MR1 mRNA CTD PMID:25811541 NCBI chr13:72,771,992...72,789,861
Ensembl chr13:72,771,984...72,789,841
JBrowse link
G Mtor mechanistic target of rapamycin kinase decreases phosphorylation ISO gefitinib results in decreased phosphorylation of MTOR protein CTD PMID:21655094 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC mRNA]; gefitinib inhibits the reaction [Tobacco Smoke Pollution results in increased expression of MUC5AC protein] CTD PMID:21544845 NCBI chr 1:214,725,482...214,756,653 JBrowse link
G Mug1 murinoglobulin 1 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of MUG1 mRNA CTD PMID:20935109 NCBI chr 4:154,676,382...154,729,288
Ensembl chr 4:154,391,647...154,729,310
JBrowse link
G Myc MYC proto-oncogene, bHLH transcription factor decreases expression ISO gefitinib results in decreased expression of MYC protein CTD PMID:17513607 NCBI chr 7:102,586,313...102,591,240
Ensembl chr 7:102,586,313...102,591,240
JBrowse link
G Myh7 myosin heavy chain 7 increases expression EXP gefitinib results in increased expression of MYH7 mRNA; gefitinib results in increased expression of MYH7 protein CTD PMID:27084042 NCBI chr15:33,605,769...33,657,761
Ensembl chr15:33,634,422...33,656,089
JBrowse link
G Ndufaf4 NADH:ubiquinone oxidoreductase complex assembly factor 4 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of NDUFAF4 mRNA CTD PMID:20935109 NCBI chr 5:39,251,370...39,256,542
Ensembl chr 5:39,251,337...39,257,512
JBrowse link
G Nfkb1 nuclear factor kappa B subunit 1 decreases expression ISO gefitinib results in decreased expression of NFKB1 mRNA CTD PMID:16685379 NCBI chr 2:240,773,520...240,890,053
Ensembl chr 2:240,773,456...240,866,689
JBrowse link
G Nfkbia NFKB inhibitor alpha multiple interactions ISO [AURKA results in increased degradation of NFKBIA protein] which results in decreased susceptibility to gefitinib CTD PMID:21216229 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nppa natriuretic peptide A increases expression
multiple interactions
EXP Gefitinib results in increased expression of NPPA mRNA; Gefitinib results in increased expression of NPPA protein
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of NPPA mRNA]
CTD PMID:32370496 NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
JBrowse link
G Nppb natriuretic peptide B increases expression EXP gefitinib results in increased expression of NPPB mRNA; gefitinib results in increased expression of NPPB protein CTD PMID:27084042 NCBI chr 5:164,796,176...164,797,538
Ensembl chr 5:164,796,185...164,797,531
JBrowse link
G Nptx2 neuronal pentraxin 2 decreases expression ISO gefitinib results in decreased expression of NPTX2 mRNA CTD PMID:16685379 NCBI chr12:12,014,638...12,025,547
Ensembl chr12:12,013,911...12,025,549
JBrowse link
G Nrl neural retina leucine zipper decreases expression ISO gefitinib results in decreased expression of NRL mRNA CTD PMID:16685379 NCBI chr15:34,197,115...34,201,408
Ensembl chr15:34,197,193...34,198,921
JBrowse link
G Osmr oncostatin M receptor affects response to substance ISO OSMR protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 2:56,107,491...56,163,522
Ensembl chr 2:56,110,777...56,151,531
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 multiple interactions
increases cleavage
ISO betulinic acid promotes the reaction [Gefitinib results in increased cleavage of PARP1 protein]; Gefitinib affects the reaction [Oxaliplatin results in increased cleavage of PARP1 protein]
gefitinib results in increased cleavage of PARP1 protein
CTD PMID:16243822, PMID:23523951, PMID:30136359 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Pcna proliferating cell nuclear antigen multiple interactions ISO Gefitinib inhibits the reaction [Folic Acid results in increased expression of PCNA protein] CTD PMID:23255615 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pcnt pericentrin decreases response to substance ISO PCNT protein results in decreased susceptibility to gefitinib CTD PMID:26298006 NCBI chr20:12,943,523...13,038,615
Ensembl chr20:12,944,786...13,038,431
JBrowse link
G Pecam1 platelet and endothelial cell adhesion molecule 1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA] CTD PMID:18424623 NCBI chr10:94,850,971...94,913,202 JBrowse link
G Pgrmc1 progesterone receptor membrane component 1 decreases response to substance ISO PGRMC1 protein results in decreased susceptibility to gefitinib CTD PMID:26298006 NCBI chr  X:123,205,869...123,213,880
Ensembl chr  X:123,205,869...123,213,882
JBrowse link
G Phlda2 pleckstrin homology-like domain, family A, member 2 affects response to substance ISO PHLDA2 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 1:216,701,345...216,704,479
Ensembl chr 1:216,702,319...216,703,534
JBrowse link
G Plau plasminogen activator, urokinase multiple interactions ISO gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]; gefitinib promotes the reaction [resveratrol inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; gefitinib promotes the reaction [resveratrol inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [EGF protein results in increased expression of PLAU mRNA]]; resveratrol promotes the reaction [gefitinib inhibits the reaction [lysophosphatidic acid results in increased expression of PLAU mRNA]] CTD PMID:23127547 NCBI chr15:3,644,296...3,650,765
Ensembl chr15:3,644,769...3,650,819
JBrowse link
G Plbd1 phospholipase B domain containing 1 affects response to substance ISO PLBD1 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 4:170,564,387...170,620,681
Ensembl chr 4:170,564,367...170,620,703
JBrowse link
G Pten phosphatase and tensin homolog multiple interactions
increases expression
EXP 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one promotes the reaction [Gefitinib results in increased expression of PTEN mRNA]
Gefitinib results in increased expression of PTEN mRNA; Gefitinib results in increased expression of PTEN protein; Gefitinib results in increased expression of PTEN protein modified form
CTD PMID:32370496 NCBI chr 1:251,421,814...251,487,634
Ensembl chr 1:251,421,596...251,487,832
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO gefitinib promotes the reaction [[zoledronic acid co-treated with 4-(5-(4-chlorophenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide] results in decreased expression of PTGS2 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of PTGS2 protein]
CTD PMID:16322342, PMID:23948867 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Pttg1 PTTG1 regulator of sister chromatid separation, securin multiple interactions
decreases response to substance
ISO gefitinib results in decreased stability of and results in decreased expression of PTTG1 protein
PTTG1 protein results in decreased susceptibility to gefitinib
CTD PMID:23523951 NCBI chr10:29,014,332...29,026,088
Ensembl chr10:29,020,049...29,026,002
JBrowse link
G Qsox1 quiescin sulfhydryl oxidase 1 increases expression ISO gefitinib results in increased expression of QSOX1 mRNA CTD PMID:16685379 NCBI chr13:73,423,396...73,460,890
Ensembl chr13:73,423,397...73,460,935
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions
decreases expression
ISO betulinic acid promotes the reaction [Gefitinib results in decreased expression of RB1 protein modified form]; Gefitinib promotes the reaction [betulinic acid results in decreased expression of RB1 protein modified form] CTD PMID:30136359 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Rbm7 RNA binding motif protein 7 affects response to substance ISO RBM7 protein affects the susceptibility to gefitinib CTD PMID:15496427 NCBI chr 8:52,823,094...52,828,134
Ensembl chr 8:52,823,096...52,828,134
JBrowse link
G Rela RELA proto-oncogene, NF-kB subunit multiple interactions
decreases response to substance
ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of RELA protein]
RELA protein results in decreased susceptibility to gefitinib
CTD PMID:19318490, PMID:21216229 NCBI chr 1:220,992,770...221,003,249
Ensembl chr 1:220,992,770...221,003,249
JBrowse link
G Rpa1 replication protein A1 increases expression ISO gefitinib results in increased expression of RPA1 mRNA CTD PMID:16685379 NCBI chr10:62,140,419...62,191,518
Ensembl chr10:62,140,419...62,191,512
JBrowse link
G Rps6kb1 ribosomal protein S6 kinase B1 decreases phosphorylation ISO gefitinib results in decreased phosphorylation of RPS6KB1 protein CTD PMID:21655094 NCBI chr10:73,824,200...73,865,503
Ensembl chr10:73,824,202...73,865,364
JBrowse link
G Rrm1 ribonucleotide reductase catalytic subunit M1 affects response to substance ISO RRM1 gene polymorphism affects the susceptibility to gefitinib CTD PMID:21264830 NCBI chr 1:167,538,387...167,562,688
Ensembl chr 1:167,538,263...167,562,688
JBrowse link
G RT1-CE5 RT1 class I, locus CE5 affects expression ISO gefitinib affects the expression of HLA-F mRNA CTD PMID:25811541 NCBI chr20:4,892,702...4,896,993
Ensembl chr20:4,892,702...4,896,991
JBrowse link
G RT1-Db1 RT1 class II, locus Db1 affects expression ISO gefitinib affects the expression of HLA-DRB1 mRNA CTD PMID:25811541 NCBI chr20:4,087,621...4,097,190
Ensembl chr20:4,087,618...4,097,190
JBrowse link
G RT1-DOa RT1 class II, locus DOa affects expression ISO gefitinib affects the expression of HLA-DOA mRNA CTD PMID:25811541 NCBI chr20:3,889,106...3,892,360
Ensembl chr20:3,889,370...3,892,449
JBrowse link
G S100a6 S100 calcium binding protein A6 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of S100A6 mRNA CTD PMID:20935109 NCBI chr 2:190,007,013...190,008,512
Ensembl chr 2:190,007,216...190,008,511
JBrowse link
G S100a8 S100 calcium binding protein A8 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of S100A8 mRNA; [gefitinib co-treated with naphthalene] affects the expression of S100A8 protein CTD PMID:20935109 NCBI chr 2:190,073,239...190,074,333
Ensembl chr 2:190,073,815...190,074,354
JBrowse link
G Serpinf1 serpin family F member 1 multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA] CTD PMID:18424623 NCBI chr10:62,241,750...62,254,145
Ensembl chr10:62,241,756...62,254,287
JBrowse link
G Sfn stratifin decreases expression ISO gefitinib results in decreased expression of SFN mRNA CTD PMID:16685379 NCBI chr 5:151,823,422...151,824,937
Ensembl chr 5:151,823,887...151,824,633
JBrowse link
G Ski SKI proto-oncogene increases expression ISO gefitinib results in increased expression of SKI mRNA CTD PMID:16685379 NCBI chr 5:172,556,196...172,623,878
Ensembl chr 5:172,559,135...172,623,899
JBrowse link
G Slc10a3 solute carrier family 10, member 3 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of SLC10A3 mRNA CTD PMID:20935109 NCBI chr  X:156,335,385...156,340,256
Ensembl chr  X:156,336,450...156,340,234
JBrowse link
G Snai2 snail family transcriptional repressor 2 affects response to substance ISO SNAI2 protein affects the susceptibility to gefitinib CTD PMID:21037017 NCBI chr11:90,404,421...90,406,730
Ensembl chr11:90,403,333...90,406,797
JBrowse link
G Sox17 SRY-box transcription factor 17 decreases localization ISO gefitinib results in decreased localization of SOX17 protein CTD PMID:24154490 NCBI chr 5:14,890,318...14,895,907
Ensembl chr 5:14,890,408...14,895,907
JBrowse link
G Sqstm1 sequestosome 1 multiple interactions
decreases expression
ISO [Gefitinib co-treated with Cisplatin] results in decreased expression of SQSTM1 protein; EGFR gene mutant form promotes the reaction [Gefitinib results in decreased expression of SQSTM1 protein] CTD PMID:25979647, PMID:27639429 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions ISO [Gefitinib co-treated with betulin] results in decreased expression of SREBF1 protein CTD PMID:27447558 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO gefitinib inhibits the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; gefitinib inhibits the reaction [EGF results in increased phosphorylation of STAT3 protein]
gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of STAT3 mRNA]; gefitinib inhibits the reaction [Cadmium Chloride results in increased phosphorylation of STAT3 protein]
CTD PMID:19318490, PMID:21787763, PMID:23948867 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Synpo synaptopodin multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of SYNPO mRNA CTD PMID:20935109 NCBI chr18:55,863,081...55,921,412
Ensembl chr18:55,865,467...55,916,220
JBrowse link
G Tek TEK receptor tyrosine kinase multiple interactions ISO gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA] CTD PMID:18424623 NCBI chr 5:113,725,717...113,852,799
Ensembl chr 5:113,725,717...113,852,799
JBrowse link
G Tert telomerase reverse transcriptase decreases expression ISO gefitinib results in decreased expression of TERT mRNA CTD PMID:17094457 NCBI chr 1:32,250,876...32,275,330
Ensembl chr 1:32,251,714...32,272,476
JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions ISO gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]] CTD PMID:21499124, PMID:21951556 NCBI chr17:24,653,342...24,670,457
Ensembl chr17:24,654,902...24,670,457
JBrowse link
G Tgfa transforming growth factor alpha decreases response to substance
multiple interactions
ISO TGFA protein results in decreased susceptibility to gefitinib
gefitinib inhibits the reaction [TGFA protein results in decreased expression of EDNRB mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of FOXF1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of KDR mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of PECAM1 mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of TEK mRNA]; gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of MDK mRNA]; gefitinib inhibits the reaction [TGFA protein results in increased expression of SERPINF1 mRNA]
5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one promotes the reaction [gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]]; gefitinib inhibits the reaction [irinotecan metabolite results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [irinotecan results in increased secretion of TGFA protein]; gefitinib inhibits the reaction [TGFA protein results in increased susceptibility to 5-((2,6-dichlorobenzyl)sulfonyl)-3-((3,5-dimethyl-4-((2-(pyrrolidin-1-ylmethyl)pyrrolidin-1-yl)carbonyl)-1H-pyrrol-2-yl)methylene)-1,3-dihydro-2H-indol-2-one]
CTD PMID:15723263, PMID:16230376, PMID:18424623, PMID:21266357 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF mRNA]; Gefitinib inhibits the reaction [Cadmium Chloride results in increased expression of TNF protein]; Gefitinib inhibits the reaction [TNF protein results in increased expression of ITGAV mRNA]; Gefitinib inhibits the reaction [TNF protein results in increased expression of MMP9 mRNA] CTD PMID:15841081, PMID:23948867 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfrsf1b TNF receptor superfamily member 1B decreases expression ISO gefitinib results in decreased expression of TNFRSF1B mRNA CTD PMID:16685379 NCBI chr 5:163,136,390...163,167,299
Ensembl chr 5:163,136,390...163,167,299
JBrowse link
G Tnni3 troponin I3, cardiac type increases secretion EXP Gefitinib results in increased secretion of TNNI3 protein CTD PMID:32370496 NCBI chr 1:72,882,806...72,886,490
Ensembl chr 1:72,882,806...72,886,488
JBrowse link
G Tp53 tumor protein p53 multiple interactions
increases expression
affects response to substance
ISO
EXP
[TP53 protein results in decreased expression of AURKA protein] which results in increased susceptibility to Gefitinib; Gefitinib inhibits the reaction [bisphenol A results in increased phosphorylation of TP53 protein]
gefitinib results in increased expression of TP53 mRNA; gefitinib results in increased expression of TP53 protein
TP53 protein affects the susceptibility to gefitinib
CTD PMID:21216229, PMID:27084042, PMID:29383186 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Trim23 tripartite motif-containing 23 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of TRIM23 mRNA CTD PMID:20935109 NCBI chr 2:34,255,300...34,288,140
Ensembl chr 2:34,255,305...34,288,139
JBrowse link
G Tsc22d1 TSC22 domain family, member 1 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of TSC22D1 mRNA CTD PMID:20935109 NCBI chr15:58,554,358...58,658,156
Ensembl chr15:58,554,374...58,658,153
JBrowse link
G Twist1 twist family bHLH transcription factor 1 affects response to substance ISO TWIST1 protein affects the susceptibility to Gefitinib CTD PMID:30993382 NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
JBrowse link
G Tyms thymidylate synthetase decreases expression
multiple interactions
ISO Gefitinib results in decreased expression of TYMS mRNA; Gefitinib results in decreased expression of TYMS protein
betulinic acid promotes the reaction [Gefitinib results in decreased expression of TYMS protein]; Gefitinib promotes the reaction [betulinic acid results in decreased expression of TYMS protein]; TYMS protein affects the susceptibility to [Gefitinib co-treated with S 1 (combination)]
CTD PMID:18347146, PMID:30136359 NCBI chr 9:121,918,875...121,931,564
Ensembl chr 9:121,918,947...121,931,564
JBrowse link
G Ulbp1 UL16 binding protein 1 multiple interactions
increases expression
ISO Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib inhibits the reaction [TFAP2A protein binds to ULBP1 promoter]]; Tetradecanoylphorbol Acetate inhibits the reaction [Gefitinib results in increased expression of ULBP1 mRNA]
Gefitinib results in increased expression of ULBP1 mRNA; Gefitinib results in increased expression of ULBP1 protein
CTD PMID:21499124, PMID:21951556 NCBI chr 1:1,181,301...1,200,526
Ensembl chr 1:1,180,932...1,220,916
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions
decreases expression
ISO
EXP
gefitinib inhibits the reaction [TGFA protein results in decreased expression of VEGFA mRNA]
gefitinib results in decreased expression of VEGFA protein
CTD PMID:15660382, PMID:18424623 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vim vimentin multiple interactions ISO Gefitinib inhibits the reaction [Folic Acid results in increased expression of VIM protein] CTD PMID:23255615 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link
G Xrcc1 X-ray repair cross complementing 1 affects response to substance ISO XRCC1 protein polymorphism affects the susceptibility to gefitinib CTD PMID:21264830 NCBI chr 1:81,412,635...81,441,680
Ensembl chr 1:81,413,353...81,441,678
JBrowse link
G Zc3h3 zinc finger CCCH type containing 3 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of ZC3H3 mRNA CTD PMID:20935109 NCBI chr 7:116,787,762...116,872,536
Ensembl chr 7:116,787,766...116,872,511
JBrowse link
G Zfp35 zinc finger protein 35 multiple interactions ISO [gefitinib co-treated with naphthalene] affects the expression of ZFP35 mRNA CTD PMID:20935109 NCBI chr18:15,883,182...15,898,803
Ensembl chr18:15,883,182...15,898,821
JBrowse link
osimertinib term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Akt1 AKT serine/threonine kinase 1 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of AKT1 protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of AKT1 protein CTD PMID:30145802, PMID:30623574, PMID:30993382 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Casp3 caspase 3 multiple interactions
increases expression
ISO Acetylcysteine inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; Vitamin E inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form] CTD PMID:28237877 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cat catalase multiple interactions
decreases response to substance
ISO CAT protein inhibits the reaction [osimertinib results in increased abundance of Hydrogen Peroxide]; CAT protein inhibits the reaction [osimertinib results in increased expression of CASP3 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]
CAT protein results in decreased susceptibility to osimertinib
CTD PMID:28237877 NCBI chr 3:93,379,872...93,412,058
Ensembl chr 3:93,379,874...93,412,058
JBrowse link
G Egf epidermal growth factor multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein] CTD PMID:30623574 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
decreases activity
ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of EGFR protein]; osimertinib inhibits the reaction [EGFR protein mutant form results in decreased susceptibility to Gefitinib]; osimertinib promotes the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of EGFR protein]; osimertinib results in decreased expression of and results in decreased phosphorylation of EGFR protein
osimertinib results in decreased activity of EGFR protein
CTD PMID:28237877, PMID:30145802, PMID:30623574, PMID:30993382 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Gpt glutamic--pyruvic transaminase increases secretion ISO osimertinib results in increased secretion of GPT protein CTD PMID:29655783 NCBI chr 7:117,759,083...117,761,932
Ensembl chr 7:117,759,083...117,761,931
JBrowse link
G Il6 interleukin 6 multiple interactions ISO osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased expression of IL6 mRNA]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased secretion of IL6 protein] CTD PMID:30623574 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK1 protein CTD PMID:30623574, PMID:30993382 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; osimertinib results in decreased expression of and results in increased phosphorylation of MAPK3 protein CTD PMID:30623574, PMID:30993382 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Parp1 poly (ADP-ribose) polymerase 1 increases expression
increases cleavage
multiple interactions
ISO osimertinib results in increased expression of PARP1 protein modified form
osimertinib results in increased cleavage of PARP1 protein
[TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; Acetylcysteine inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; CAT protein inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]; Vitamin E inhibits the reaction [osimertinib results in increased expression of PARP1 protein modified form]
CTD PMID:28237877, PMID:30171258 NCBI chr13:98,857,255...98,889,444
Ensembl chr13:98,857,177...98,889,716
JBrowse link
G Sqstm1 sequestosome 1 decreases expression ISO osimertinib results in decreased expression of SQSTM1 protein CTD PMID:30145802 NCBI chr10:35,704,728...35,716,316
Ensembl chr10:35,704,730...35,716,294
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions ISO osimertinib affects the reaction [EGF protein results in increased phosphorylation of STAT3 protein]; osimertinib inhibits the reaction [Derp2 allergen, Dermatophagoides pteronyssinus results in increased phosphorylation of STAT3 protein] CTD PMID:30623574 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Twist1 twist family bHLH transcription factor 1 decreases response to substance
multiple interactions
affects response to substance
ISO TWIST1 protein results in decreased susceptibility to osimertinib
[TWIST1 protein results in decreased susceptibility to osimertinib] which results in decreased cleavage of PARP1 protein; TWIST1 protein inhibits the reaction [osimertinib results in increased cleavage of PARP1 protein]
TWIST1 protein affects the susceptibility to osimertinib
CTD PMID:30171258, PMID:30993382 NCBI chr 6:53,401,241...53,403,235
Ensembl chr 6:53,401,109...53,403,214
JBrowse link
PD 168393 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Agt angiotensinogen multiple interactions EXP PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein] CTD PMID:25398788 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein] CTD PMID:25398788 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Bad BCL2-associated agonist of cell death multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased expression of BAD protein CTD PMID:16413505 NCBI chr 1:222,198,516...222,207,459
Ensembl chr 1:222,198,534...222,207,453
JBrowse link
G Casp3 caspase 3 multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased cleavage of and results in increased activity of CASP3 protein CTD PMID:16413505 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Ccl2 C-C motif chemokine ligand 2 multiple interactions
increases expression
ISO PD168393 results in increased expression of and results in increased secretion of CCL2 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CCL2 mRNA] CTD PMID:21967610 NCBI chr10:69,412,065...69,413,863
Ensembl chr10:69,412,017...69,413,870
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased expression of CDKN1A protein CTD PMID:16413505 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Cxcl10 C-X-C motif chemokine ligand 10 multiple interactions
increases expression
ISO acteoside inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein]; PD168393 results in increased expression of and results in increased secretion of CXCL10 protein; polydatin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Quercetin inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased expression of CXCL10 mRNA]; Resveratrol inhibits the reaction [PD168393 results in increased secretion of CXCL10 protein] CTD PMID:21967610 NCBI chr14:17,210,733...17,212,930
Ensembl chr14:17,210,733...17,212,930
JBrowse link
G Cycs cytochrome c, somatic multiple interactions ISO [PD168393 co-treated with Paclitaxel] affects the localization of CYCS protein CTD PMID:16413505 NCBI chr 4:80,331,226...80,333,326
Ensembl chr 4:80,331,227...80,333,326
JBrowse link
G Egfr epidermal growth factor receptor affects localization
multiple interactions
decreases phosphorylation
ISO
EXP
PD168393 affects the localization of EGFR protein; PD168393 affects the localization of EGFR protein modified form
PD168393 inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]
[PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of EGFR protein; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of EGFR protein]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein]
PD168393 results in decreased phosphorylation of EGFR protein
CTD PMID:16413505, PMID:21967610, PMID:23527233, PMID:25398788 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Jak3 Janus kinase 3 multiple interactions ISO PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of JAK3 protein] CTD PMID:16778083 NCBI chr16:20,107,471...20,120,678
Ensembl chr16:20,109,200...20,120,668
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK1 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK1 protein]; PD168393 inhibits the reaction [Resveratrol results in increased phosphorylation of MAPK1 protein]
PD168393 results in decreased phosphorylation of MAPK1 protein
CTD PMID:16413505, PMID:16778083, PMID:23527233 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO [PD168393 co-treated with Paclitaxel] results in decreased phosphorylation of and results in decreased activity of MAPK3 protein; PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK3 protein]; PD168393 inhibits the reaction [resveratrol results in increased phosphorylation of MAPK3 protein]
PD168393 results in decreased phosphorylation of MAPK3 protein
CTD PMID:16413505, PMID:16778083, PMID:23527233 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased phosphorylation of MAPK8 protein] CTD PMID:16778083 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mmp3 matrix metallopeptidase 3 multiple interactions ISO PD168393 inhibits the reaction [2,2',4,6,6'-pentachlorobiphenyl results in increased expression of MMP3 mRNA] CTD PMID:29535049 NCBI chr 8:5,676,608...5,698,579
Ensembl chr 8:5,676,665...5,698,579
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions EXP PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; PD168393 inhibits the reaction [AGT protein results in increased expression of SP1 mRNA] CTD PMID:25398788 NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions EXP PD168393 inhibits the reaction [Glucose results in increased activity of and results in increased cleavage of SREBF1 protein] CTD PMID:22031849 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions ISO PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein modified form]; PD168393 inhibits the reaction [TGFA protein affects the localization of EGFR protein] CTD PMID:21967610 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP PD168393 inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]] CTD PMID:25398788 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO [PD168393 co-treated with Paclitaxel] results in increased expression of TP53 protein CTD PMID:16413505 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
tyrphostin AG 1478 term browser
Symbol Object Name Qualifiers Evidence Notes Source PubMed Reference(s) RGD Reference(s) Position
G Abcc2 ATP binding cassette subfamily C member 2 multiple interactions EXP RTKI cpd inhibits the reaction [estradiol-17 beta-glucuronide affects the localization of and results in decreased activity of ABCC2 protein] CTD PMID:25813982 NCBI chr 1:263,554,426...263,612,556
Ensembl chr 1:263,554,453...263,613,252
JBrowse link
G Ace angiotensin I converting enzyme multiple interactions EXP RTKI cpd inhibits the reaction [Aldosterone results in increased expression of ACE mRNA] CTD PMID:15932931 NCBI chr10:94,170,766...94,213,831
Ensembl chr10:94,170,766...94,187,822
JBrowse link
G Adrb1 adrenoceptor beta 1 multiple interactions ISO RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]] CTD PMID:18787115 NCBI chr 1:277,537,585...277,538,985
Ensembl chr 1:277,537,585...277,538,985
JBrowse link
G Agt angiotensinogen multiple interactions EXP RTKI cpd inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; RTKI cpd inhibits the reaction [AGT protein results in increased expression of SP1 mRNA]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein] CTD PMID:15849355, PMID:25398788 NCBI chr19:57,321,594...57,333,460
Ensembl chr19:57,321,640...57,333,433
JBrowse link
G Akt1 AKT serine/threonine kinase 1 multiple interactions EXP
ISO
RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of AKT1 protein]]; RTKI cpd inhibits the reaction [Zinc Sulfate results in increased phosphorylation of AKT1 protein]
RTKI cpd inhibits the reaction [Cadmium Chloride results in increased cleavage of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of AKT1 protein]
CTD PMID:11309286, PMID:15177934, PMID:15849355, PMID:19233221, PMID:19946718, PMID:24015256, PMID:24071787, PMID:25118938, PMID:25398788 NCBI chr 6:137,218,398...137,239,970
Ensembl chr 6:137,218,376...137,236,258
JBrowse link
G Alb albumin multiple interactions ISO RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CXCL8 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK3 protein] CTD PMID:16908450 NCBI chr14:19,176,275...19,191,793
Ensembl chr14:19,176,277...19,191,863
JBrowse link
G Alox5 arachidonate 5-lipoxygenase multiple interactions ISO [RTKI cpd co-treated with AG 1879] inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]; RTKI cpd inhibits the reaction [Nicotine results in increased expression of ALOX5 protein]
RTKI cpd inhibits the reaction [Acrolein results in increased expression of ALOX5 protein]
CTD PMID:14569062, PMID:20153347 NCBI chr 4:148,398,004...148,446,308
Ensembl chr 4:148,398,892...148,446,303
JBrowse link
G Angpt1 angiopoietin 1 multiple interactions ISO RTKI cpd inhibits the reaction [Iloprost results in increased expression of ANGPT1 mRNA] CTD PMID:16373414 NCBI chr 7:81,338,327...81,592,459
Ensembl chr 7:81,342,280...81,592,206
JBrowse link
G Angpt2 angiopoietin 2 multiple interactions ISO RTKI cpd inhibits the reaction [Iloprost results in increased expression of ANGPT2 mRNA] CTD PMID:16373414 NCBI chr16:75,966,480...76,016,147
Ensembl chr16:75,966,352...76,016,195
JBrowse link
G Ar androgen receptor multiple interactions ISO RTKI cpd inhibits the reaction [EGF protein results in decreased expression of AR protein]; RTKI cpd inhibits the reaction [Particulate Matter results in increased secretion of AR protein]; RTKI cpd inhibits the reaction [Vehicle Emissions results in increased secretion of AR protein] CTD PMID:16472761, PMID:24555532 NCBI chr  X:67,656,253...67,828,998
Ensembl chr  X:67,656,253...67,829,026
JBrowse link
G Areg amphiregulin multiple interactions
decreases activity
ISO RTKI cpd inhibits the reaction [[AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein]
RTKI cpd results in decreased activity of AREG protein
CTD PMID:15706222, PMID:21185374 NCBI chr14:18,521,921...18,531,179
Ensembl chr14:18,521,930...18,531,179
JBrowse link
G Atf1 activating transcription factor 1 multiple interactions ISO RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of ATF1 protein] CTD PMID:16671086 NCBI chr 7:141,882,261...141,924,790
Ensembl chr 7:141,882,251...141,924,788
JBrowse link
G Atp1a2 ATPase Na+/K+ transporting subunit alpha 2 multiple interactions ISO RTKI cpd inhibits the reaction [Ammonia results in increased expression of ATP1A2 mRNA]; RTKI cpd inhibits the reaction [Ammonia results in increased expression of ATP1A2 protein] CTD PMID:20447429 NCBI chr13:90,651,682...90,676,629
Ensembl chr13:90,651,686...90,676,629
JBrowse link
G Bax BCL2 associated X, apoptosis regulator multiple interactions EXP RTKI cpd results in increased expression of and results in increased activity of BAX protein CTD PMID:18371937 NCBI chr 1:101,451,801...101,457,207
Ensembl chr 1:101,451,802...101,457,207
JBrowse link
G Bcl2l1 Bcl2-like 1 decreases expression EXP RTKI cpd results in decreased expression of BCL2L1 mRNA; RTKI cpd results in decreased expression of BCL2L1 protein CTD PMID:18371937 NCBI chr 3:148,259,594...148,314,191
Ensembl chr 3:148,259,596...148,313,810
JBrowse link
G Birc5 baculoviral IAP repeat-containing 5 multiple interactions
decreases expression
ISO [RTKI cpd results in decreased activity of EGFR protein] which results in decreased expression of BIRC5 protein
RTKI cpd results in decreased expression of BIRC5 protein
CTD PMID:21268125, PMID:29974605 NCBI chr10:106,856,097...106,864,419
Ensembl chr10:106,856,097...106,864,413
JBrowse link
G Bmp4 bone morphogenetic protein 4 multiple interactions ISO RTKI cpd inhibits the reaction [antimonite results in decreased expression of BMP4 mRNA]; RTKI cpd inhibits the reaction [arsenite results in decreased expression of BMP4 mRNA] CTD PMID:17400267 NCBI chr15:20,776,060...20,791,013
Ensembl chr15:20,776,054...20,822,740
JBrowse link
G Casp3 caspase 3 multiple interactions EXP RTKI cpd promotes the reaction [Cadmium Chloride results in increased cleavage of CASP3 protein] CTD PMID:19233221 NCBI chr16:48,845,011...48,863,249
Ensembl chr16:48,845,012...48,863,204
JBrowse link
G Cav1 caveolin 1 multiple interactions ISO RTKI cpd inhibits the reaction [Rosiglitazone results in increased expression of CAV1] CTD PMID:18507034 NCBI chr 4:44,597,123...44,630,206
Ensembl chr 4:44,597,123...44,630,200
JBrowse link
G Ccnb1 cyclin B1 multiple interactions ISO RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CCNB1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNB1 protein] CTD PMID:26385184 NCBI chr 2:30,782,133...30,791,106
Ensembl chr 2:30,783,915...30,791,221
JBrowse link
G Ccnd1 cyclin D1 multiple interactions
decreases expression
ISO RTKI cpd inhibits the reaction [[Fulvestrant co-treated with bisphenol A] results in decreased expression of CCND1 mRNA]
RTKI cpd results in decreased expression of CCND1 protein
CTD PMID:28446726, PMID:29974605 NCBI chr 1:218,090,750...218,100,447
Ensembl chr 1:218,090,750...218,100,325
JBrowse link
G Ccne1 cyclin E1 multiple interactions
decreases expression
ISO RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CCNE1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNE1 protein]
RTKI cpd results in decreased expression of CCNE1 protein
CTD PMID:15923621, PMID:26385184 NCBI chr 1:94,485,830...94,495,112
Ensembl chr 1:94,485,832...94,494,980
JBrowse link
G Cdh1 cadherin 1 increases expression ISO RTKI cpd results in increased expression of CDH1 protein CTD PMID:25856345 NCBI chr19:38,768,467...38,838,395
Ensembl chr19:38,768,467...38,838,395
JBrowse link
G Cdk1 cyclin-dependent kinase 1 multiple interactions ISO RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CDK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK1 protein] CTD PMID:26385184 NCBI chr20:20,576,341...20,591,510
Ensembl chr20:20,576,377...20,591,549
JBrowse link
G Cdk2 cyclin dependent kinase 2 multiple interactions ISO RTKI cpd inhibits the reaction [Cadmium Chloride results in increased expression of CDK2 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK2 protein] CTD PMID:26385184 NCBI chr 7:3,124,953...3,132,533
Ensembl chr 7:3,124,954...3,132,457
JBrowse link
G Cdkn1a cyclin-dependent kinase inhibitor 1A multiple interactions ISO RTKI cpd inhibits the reaction [Arsenic Trioxide results in increased expression of CDKN1A protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of CDKN1A protein] CTD PMID:15734884, PMID:16283431 NCBI chr20:6,348,422...6,358,864
Ensembl chr20:6,351,458...6,358,864
JBrowse link
G Creb1 cAMP responsive element binding protein 1 multiple interactions ISO
EXP
RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of CREB1 protein]
RTKI cpd inhibits the reaction [Metribolone results in increased phosphorylation of CREB1 protein]
RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of CREB1 protein]; RTKI cpd inhibits the reaction [Colforsin results in increased phosphorylation of CREB1 protein]
CTD PMID:16671086, PMID:17272394, PMID:17322281 NCBI chr 9:71,229,753...71,298,994
Ensembl chr 9:71,230,108...71,293,435
JBrowse link
G Csf2 colony stimulating factor 2 multiple interactions ISO RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased expression of CSF2 protein]; RTKI cpd inhibits the reaction [Particulate Matter results in increased secretion of CSF2 protein] CTD PMID:16908450, PMID:19460412, PMID:22581348 NCBI chr10:39,602,089...39,604,070
Ensembl chr10:39,602,089...39,604,070
JBrowse link
G Ctnnb1 catenin beta 1 multiple interactions
decreases expression
ISO RTKI cpd inhibits the reaction [arsenite affects the localization of CTNNB1 protein]
RTKI cpd results in decreased expression of CTNNB1 protein
CTD PMID:17400267, PMID:29974605 NCBI chr 8:129,601,511...129,628,378
Ensembl chr 8:129,617,812...129,627,372
JBrowse link
G Cyld CYLD lysine 63 deubiquitinase increases expression ISO [RTKI cpd results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein; RTKI cpd results in increased expression of CYLD mRNA; RTKI cpd results in increased expression of CYLD protein CTD PMID:21109933 NCBI chr19:19,264,984...19,323,817
Ensembl chr19:19,265,164...19,315,357
JBrowse link
G Dnmt3a DNA methyltransferase 3 alpha multiple interactions ISO RTKI cpd inhibits the reaction [lead nitrate results in decreased expression of DNMT3A mRNA] CTD PMID:24639330 NCBI chr 6:28,205,375...28,346,052
Ensembl chr 6:28,235,695...28,340,577
JBrowse link
G Edn1 endothelin 1 multiple interactions ISO
EXP
RTKI cpd inhibits the reaction [Doxorubicin results in increased expression of EDN1 mRNA]
RTKI cpd inhibits the reaction [Doxorubicin results in increased expression of EDN1 mRNA]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]]
CTD PMID:16261333, PMID:17974986 NCBI chr17:22,136,814...22,143,745
Ensembl chr17:22,137,324...22,143,324
JBrowse link
G Egf epidermal growth factor multiple interactions ISO
EXP
RTKI cpd inhibits the reaction [EGF protein results in decreased expression of and results in decreased secretion of KLK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in decreased expression of AR protein]; RTKI cpd inhibits the reaction [EGF protein results in increased abundance of Calcium]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of STAT3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNB1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CCNE1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of CDK2 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of GPER1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of SRC protein]; RTKI cpd inhibits the reaction [EGF protein results in increased secretion of MMP1 protein]; RTKI cpd inhibits the reaction [Estradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]]
RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK7 protein]
RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of AKT1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased susceptibility to Desoxycorticosterone]
CTD PMID:10516208, PMID:11309286, PMID:11527950, PMID:11751714, PMID:14737115, PMID:15849355, PMID:16472761, PMID:17656145, PMID:19749156, PMID:21185374, PMID:25841994, PMID:25856345, PMID:25969534, PMID:26385184, PMID:28974440 NCBI chr 2:68,820,616...68,895,537 JBrowse link
G Egfr epidermal growth factor receptor multiple interactions
decreases expression
decreases phosphorylation
decreases activity
ISO
EXP
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased chemical synthesis of Oxygen]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of STAT5B protein]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to 5-methoxy-1,2-dimethyl-3-((4-nitrophenoxy)methyl)indole-4,7-dione; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to FSHB protein; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to Hexachlorobenzene; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to Topotecan; RTKI cpd inhibits the reaction [[AREG protein co-treated with Estradiol] results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Cadmium results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Capsaicin results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [EGFR protein binds to GPER1 protein]; RTKI cpd inhibits the reaction [Estradiol promotes the reaction [EGF protein results in increased phosphorylation of EGFR protein]]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [lead nitrate results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Win 55212-2 results in increased phosphorylation of EGFR protein]
RTKI cpd results in decreased expression of EGFR protein modified form
RTKI cpd results in decreased phosphorylation of EGFR protein
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Genistein results in increased secretion of Testosterone]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [AGT protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [estradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [sodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein]]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of EGFR protein]
[[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased expression of MT2 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased expression of BIRC5 protein; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased phosphorylation of STAT3 protein; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to butaprost; RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Arsenic affects the localization of EGFR protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [Fluoxetine results in increased phosphorylation of EGFR protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [Sodium Chloride results in increased phosphorylation of EGFR protein]; RTKI cpd results in decreased phosphorylation of and results in decreased activity of EGFR protein
CTD PMID:9710602, PMID:12794006, PMID:15177934, PMID:15459120, PMID:15504454, PMID:15531749, PMID:15574683, PMID:15849355, PMID:15923621, PMID:16261333, PMID:16472761, PMID:18618485, PMID:18633435, PMID:18758753, PMID:18787115, PMID:19059320, PMID:19133285, PMID:19233221, PMID:19749156, PMID:19854188, PMID:20433816, PMID:20619260, PMID:20660715, PMID:20850495, PMID:21185374, PMID:21205633, PMID:21220312, PMID:21268125, PMID:21300668, PMID:21520325, PMID:21568938, PMID:23376140, PMID:23538097, PMID:23673518, PMID:25343777, PMID:25398788, PMID:25813982, PMID:25856345, PMID:25969534, PMID:26385184, PMID:26514923, PMID:27071941, PMID:28974440, PMID:29974605, PMID:32159786 NCBI chr14:99,919,485...100,104,136
Ensembl chr14:99,919,485...100,098,796
JBrowse link
G Egr1 early growth response 1 multiple interactions ISO RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of EGR1 protein] CTD PMID:15292961 NCBI chr18:27,657,903...27,660,101
Ensembl chr18:27,657,628...27,661,429
JBrowse link
G Erbb2 erb-b2 receptor tyrosine kinase 2 multiple interactions ISO [RTKI cpd co-treated with AG-879] results in decreased phosphorylation of ERBB2 protein CTD PMID:18618485 NCBI chr10:86,367,596...86,391,728
Ensembl chr10:86,367,596...86,391,728
JBrowse link
G Esr1 estrogen receptor 1 multiple interactions ISO RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of ESR1 protein] CTD PMID:21813366 NCBI chr 1:41,192,029...41,594,799
Ensembl chr 1:41,192,824...41,594,796
JBrowse link
G F11r F11 receptor multiple interactions ISO RTKI cpd inhibits the reaction [Poly I-C results in decreased expression of F11R protein] CTD PMID:20932985 NCBI chr13:89,826,272...89,850,151
Ensembl chr13:89,826,254...89,850,612
JBrowse link
G Fgf2 fibroblast growth factor 2 multiple interactions ISO RTKI cpd inhibits the reaction [Iloprost results in increased expression of FGF2 mRNA] CTD PMID:16373414 NCBI chr 2:124,081,072...124,134,133
Ensembl chr 2:124,081,072...124,134,681
JBrowse link
G Flt1 Fms related receptor tyrosine kinase 1 multiple interactions ISO RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased secretion of FLT1 protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased secretion of FLT1 protein] CTD PMID:21762757 NCBI chr12:9,033,993...9,205,886
Ensembl chr12:9,034,308...9,205,905
JBrowse link
G Fos Fos proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO
EXP
RTKI cpd inhibits the reaction [afimoxifene results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [afimoxifene results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Atrazine results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [EGF protein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Estradiol results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Genistein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [Quercetin results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of FOS protein]
RTKI cpd inhibits the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [[Fulvestrant co-treated with bisphenol A] results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [bisphenol A promotes the reaction [FOS protein binds to GPER1 promoter]]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [Estradiol results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOS mRNA]
RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of FOS mRNA]; RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of FOS mRNA]
CTD PMID:9710602, PMID:10516208, PMID:12154012, PMID:15090535, PMID:18758753, PMID:19749156, PMID:19935718, PMID:21813366, PMID:23274518, PMID:25616260, PMID:28446726 NCBI chr 6:109,300,433...109,303,299
Ensembl chr 6:109,300,433...109,303,299
JBrowse link
G Fosb FosB proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOSB mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of FOSB protein] CTD PMID:18758753 NCBI chr 1:80,214,691...80,221,417
Ensembl chr 1:80,214,494...80,221,710
JBrowse link
G Foxo3 forkhead box O3 multiple interactions ISO [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of FOXO3 protein] CTD PMID:23673518 NCBI chr20:46,428,078...46,519,156
Ensembl chr20:46,428,124...46,519,144
JBrowse link
G Fshb follicle stimulating hormone subunit beta multiple interactions ISO
EXP
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Hyaluronic Acid]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [FSHB protein results in increased chemical synthesis of Progesterone]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased susceptibility to FSHB protein
RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane inhibits the reaction [FSHB protein results in increased expression of LHCGR mRNA]]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of AKT1 protein]]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd promotes the reaction [FSHB protein results in increased expression of LHCGR mRNA]
CTD PMID:21520325, PMID:24071787 NCBI chr 3:98,088,321...98,092,131
Ensembl chr 3:98,088,324...98,092,131
JBrowse link
G Gast gastrin multiple interactions ISO RTKI cpd inhibits the reaction [lead acetate results in increased expression of GAST mRNA] CTD PMID:23765435 NCBI chr10:88,245,532...88,248,485
Ensembl chr10:88,245,532...88,248,484
JBrowse link
G Gclc glutamate-cysteine ligase, catalytic subunit multiple interactions
decreases expression
EXP Doxorubicin promotes the reaction [RTKI cpd results in decreased expression of GCLC protein] CTD PMID:18371937 NCBI chr 8:85,059,051...85,097,471
Ensembl chr 8:85,059,051...85,097,468
JBrowse link
G Gnaq G protein subunit alpha q multiple interactions EXP RTKI cpd inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]] CTD PMID:14676212 NCBI chr 1:233,382,778...233,622,584
Ensembl chr 1:233,382,708...233,622,786
JBrowse link
G Gper1 G protein-coupled estrogen receptor 1 multiple interactions ISO
EXP
RTKI cpd inhibits the reaction [EGF protein results in increased expression of GPER1 protein]; RTKI cpd inhibits the reaction [EGFR protein binds to GPER1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of GPER1 protein]
RTKI cpd inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]
RTKI cpd inhibits the reaction [bisphenol A promotes the reaction [FOS protein binds to GPER1 promoter]]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of GPER1 mRNA]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of GPER1 protein]
CTD PMID:19749156, PMID:22645130, PMID:23274518 NCBI chr12:17,309,122...17,315,267
Ensembl chr12:17,309,834...17,311,112
JBrowse link
G Has2 hyaluronan synthase 2 multiple interactions EXP RTKI cpd inhibits the reaction [LHB protein results in increased expression of HAS2 mRNA] CTD PMID:15459120 NCBI chr 7:96,438,046...96,464,049
Ensembl chr 7:96,438,046...96,464,049
JBrowse link
G Hbegf heparin-binding EGF-like growth factor multiple interactions
increases expression
decreases expression
ISO
EXP
RTKI cpd inhibits the reaction [vanadium pentoxide results in increased expression of HBEGF mRNA]
RTKI cpd results in increased expression of HBEGF mRNA
RTKI cpd results in decreased expression of HBEGF mRNA; RTKI cpd results in decreased expression of HBEGF protein
CTD PMID:11159045, PMID:22048644, PMID:26800359 NCBI chr18:29,330,302...29,340,185
Ensembl chr18:29,329,764...29,340,403
JBrowse link
G Hes1 hes family bHLH transcription factor 1 multiple interactions ISO RTKI cpd inhibits the reaction [arsenite results in decreased expression of HES1 mRNA] CTD PMID:18633435 NCBI chr11:74,312,837...74,315,249
Ensembl chr11:74,312,806...74,315,248
JBrowse link
G Hmox1 heme oxygenase 1 multiple interactions ISO RTKI cpd inhibits the reaction [arsenite results in increased expression of HMOX1 protein] CTD PMID:17196236 NCBI chr19:14,508,634...14,515,455
Ensembl chr19:14,508,616...14,515,456
JBrowse link
G Htr2b 5-hydroxytryptamine receptor 2B multiple interactions ISO RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein] CTD PMID:18758753 NCBI chr 9:93,112,781...93,130,135
Ensembl chr 9:93,112,805...93,125,014
JBrowse link
G Il6 interleukin 6 multiple interactions
decreases expression
ISO RTKI cpd affects the reaction [Capsaicin results in increased secretion of IL6 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane results in increased expression of IL6 protein]; RTKI cpd inhibits the reaction [pentabromodiphenyl ether results in increased expression of IL6 protein]; RTKI cpd inhibits the reaction [Silicon Dioxide analog results in increased secretion of IL6 protein]; RTKI cpd inhibits the reaction [tetrabromobisphenol A results in increased expression of IL6 protein]
RTKI cpd results in decreased expression of IL6 protein
CTD PMID:20619260, PMID:24184330, PMID:24844442, PMID:26718265 NCBI chr 4:3,043,231...3,047,807
Ensembl chr 4:3,043,231...3,047,807
JBrowse link
G Ivl involucrin multiple interactions
increases expression
ISO RTKI cpd inhibits the reaction [arsenite results in decreased expression of IVL mRNA]
RTKI cpd results in increased expression of IVL protein
CTD PMID:18633435 NCBI chr 2:192,761,171...192,773,346
Ensembl chr 2:192,761,538...192,763,577
JBrowse link
G Jag1 jagged canonical Notch ligand 1 multiple interactions ISO RTKI cpd inhibits the reaction [arsenite results in decreased expression of JAG1 mRNA]; RTKI cpd inhibits the reaction [arsenite results in decreased expression of JAG1 protein] CTD PMID:18633435 NCBI chr 3:130,079,361...130,114,781
Ensembl chr 3:130,079,361...130,114,770
JBrowse link
G Jak3 Janus kinase 3 multiple interactions ISO RTKI cpd results in decreased phosphorylation of and results in decreased activity of JAK3 protein CTD PMID:16932349 NCBI chr16:20,107,471...20,120,678
Ensembl chr16:20,109,200...20,120,668
JBrowse link
G Jun Jun proto-oncogene, AP-1 transcription factor subunit multiple interactions ISO
EXP
RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of JUN protein]
RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of JUN mRNA]
RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of JUN mRNA]
CTD PMID:9710602, PMID:11329622, PMID:12154012 NCBI chr 5:114,011,184...114,014,277
Ensembl chr 5:114,011,189...114,014,277
JBrowse link
G Krt1 keratin 1 increases expression ISO RTKI cpd results in increased expression of KRT1 protein CTD PMID:18633435 NCBI chr 7:143,448,318...143,453,544
Ensembl chr 7:143,448,318...143,453,544
JBrowse link
G Krt10 keratin 10 multiple interactions ISO RTKI cpd inhibits the reaction [arsenite results in decreased expression of KRT10 mRNA]; RTKI cpd inhibits the reaction [arsenite results in decreased expression of KRT10 protein] CTD PMID:18633435 NCBI chr10:87,296,445...87,301,307
Ensembl chr10:87,296,451...87,300,736
JBrowse link
G Lhb luteinizing hormone subunit beta multiple interactions ISO
EXP
RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]
RTKI cpd inhibits the reaction [LHB protein results in increased expression of HAS2 mRNA]; RTKI cpd inhibits the reaction [LHB protein results in increased expression of PTGS2 mRNA]; RTKI cpd inhibits the reaction [LHB protein results in increased expression of TNFAIP6 mRNA]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of EGFR protein]
CTD PMID:15459120, PMID:21220312 NCBI chr 1:101,409,992...101,413,725
Ensembl chr 1:101,410,019...101,413,724
JBrowse link
G Lhcgr luteinizing hormone/choriogonadotropin receptor multiple interactions EXP RTKI cpd inhibits the reaction [hexabromocyclododecane inhibits the reaction [FSHB protein results in increased expression of LHCGR mRNA]]; RTKI cpd promotes the reaction [FSHB protein results in increased expression of LHCGR mRNA] CTD PMID:24071787 NCBI chr 6:12,493,182...12,554,482
Ensembl chr 6:12,493,943...12,554,439
JBrowse link
G Map2k1 mitogen activated protein kinase kinase 1 multiple interactions EXP RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAP2K1 protein] CTD PMID:16269455 NCBI chr 8:69,134,218...69,722,573
Ensembl chr 8:69,134,223...69,164,758
JBrowse link
G Map2k2 mitogen activated protein kinase kinase 2 multiple interactions EXP RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAP2K2 protein] CTD PMID:16269455 NCBI chr 7:11,458,971...11,478,520
Ensembl chr 7:11,458,967...11,478,489
JBrowse link
G Mapk1 mitogen activated protein kinase 1 multiple interactions
decreases phosphorylation
ISO
EXP
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK1 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [arsenic acid results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [arsenite results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Atrazine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Calcitriol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Diacetyl results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Histamine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Iloprost results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [lead nitrate results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Lead results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd results in decreased phosphorylation of and results in decreased activity of MAPK1 protein
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein]
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Metribolone results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAPK1 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [Zinc Sulfate results in increased phosphorylation of MAPK1 protein]
RTKI cpd results in decreased phosphorylation of MAPK1 protein
CTD PMID:9710602, PMID:10516208, PMID:11309286, PMID:11329622, PMID:12761878, PMID:14674888, PMID:14676212, PMID:14737115, PMID:15177934, PMID:15247267, PMID:15319441, PMID:15504454, PMID:15574683, PMID:15843167, PMID:16261333, PMID:16269455, PMID:16373414, PMID:16671086, PMID:16908450, PMID:17272394, PMID:17656145, PMID:18360054, PMID:18758753, PMID:18787115, PMID:19233221, PMID:19850060, PMID:19854188, PMID:19946718, PMID:20153347, PMID:20466046, PMID:20660715, PMID:20850495, PMID:20875696, PMID:21205633, PMID:21220312, PMID:21300668, PMID:21762757, PMID:22552965, PMID:23376140, PMID:23538097, PMID:23765435, PMID:24015256, PMID:24071787, PMID:24106166, PMID:25312822, PMID:25343777, PMID:25616260, PMID:25744307, PMID:25856345, PMID:26006730, PMID:26385184, PMID:26514923, PMID:27071941, PMID:28446726, PMID:28974440, PMID:30851105, PMID:31075703 NCBI chr11:88,203,863...88,273,301
Ensembl chr11:88,211,599...88,273,254
JBrowse link
G Mapk14 mitogen activated protein kinase 14 multiple interactions ISO RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK14 protein] CTD PMID:11329622 NCBI chr20:5,933,290...5,995,137
Ensembl chr20:5,933,303...5,995,137
JBrowse link
G Mapk3 mitogen activated protein kinase 3 multiple interactions
decreases phosphorylation
ISO
EXP
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of MAPK3 protein]; [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [[Toluene 2,4-Diisocyanate binds to ALB protein] which results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Alprenolol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [arsenic acid results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [arsenite results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Atrazine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Calcitriol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Carvedilol promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Diacetyl results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Estradiol results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Histamine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Iloprost results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [lead acetate results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [lead nitrate results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Lead results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Pyocyanine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd results in decreased phosphorylation of and results in decreased activity of MAPK3 protein
[RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [[Fluoxetine results in increased activity of HTR2B protein] which results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [bisphenol A results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Homocysteine results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [LHB protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein]
RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Doxorubicin results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [EGFR protein affects the reaction [EDN1 protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [hexabromocyclododecane promotes the reaction [FSHB protein results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Metribolone results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Oleylethanolamide results in increased phosphorylation of MAPK3 protein]; RTKI cpd inhibits the reaction [Phenylephrine results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Uridine Triphosphate results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Zinc Sulfate results in increased phosphorylation of MAPK3 protein]
RTKI cpd results in decreased phosphorylation of MAPK3 protein
CTD PMID:9710602, PMID:10516208, PMID:11309286, PMID:11329622, PMID:12761878, PMID:14674888, PMID:14676212, PMID:14737115, PMID:15177934, PMID:15247267, PMID:15319441, PMID:15504454, PMID:15574683, PMID:15843167, PMID:16261333, PMID:16269455, PMID:16373414, PMID:16671086, PMID:16908450, PMID:17272394, PMID:17656145, PMID:18360054, PMID:18758753, PMID:18787115, PMID:19233221, PMID:19850060, PMID:19854188, PMID:19946718, PMID:20153347, PMID:20466046, PMID:20660715, PMID:20850495, PMID:20875696, PMID:21205633, PMID:21220312, PMID:21300668, PMID:21762757, PMID:22552965, PMID:23376140, PMID:23538097, PMID:23765435, PMID:24015256, PMID:24071787, PMID:24106166, PMID:25312822, PMID:25343777, PMID:25616260, PMID:25744307, PMID:25856345, PMID:26006730, PMID:26385184, PMID:26514923, PMID:27071941, PMID:28446726, PMID:28974440, PMID:30851105, PMID:31075703 NCBI chr 1:198,192,773...198,198,975
Ensembl chr 1:198,192,773...198,198,975
JBrowse link
G Mapk7 mitogen-activated protein kinase 7 multiple interactions ISO RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of MAPK7 protein] CTD PMID:14737115 NCBI chr10:47,768,592...47,775,130
Ensembl chr10:47,766,680...47,775,055
JBrowse link
G Mapk8 mitogen-activated protein kinase 8 multiple interactions ISO
EXP
RTKI cpd inhibits the reaction [Acrolein results in increased phosphorylation of MAPK8 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK8 protein]
RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased activity of MAPK8 protein]
CTD PMID:11329622, PMID:15574683, PMID:26514923 NCBI chr16:9,620,854...9,709,342
Ensembl chr16:9,625,177...9,709,347
JBrowse link
G Mapk9 mitogen-activated protein kinase 9 multiple interactions ISO RTKI cpd inhibits the reaction [Cadmium results in increased phosphorylation of MAPK9 protein] CTD PMID:26514923 NCBI chr10:35,333,859...35,374,364
Ensembl chr10:35,333,859...35,374,355
JBrowse link
G Mcl1 MCL1 apoptosis regulator, BCL2 family member decreases expression EXP RTKI cpd results in decreased expression of MCL1 mRNA; RTKI cpd results in decreased expression of MCL1 protein CTD PMID:18371937 NCBI chr 2:197,786,212...197,788,992 JBrowse link
G Mir126b microRNA 126b multiple interactions ISO RTKI cpd promotes the reaction [Asbestos, Crocidolite results in increased expression of MIR126 mRNA] CTD PMID:32006662 NCBI chr 3:4,042,488...4,042,560 JBrowse link
G Mir21 microRNA 21 multiple interactions ISO RTKI cpd inhibits the reaction [1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone results in increased expression of MIR21 mRNA]; RTKI cpd inhibits the reaction [Dehydroepiandrosterone results in increased expression of MIR21 mRNA] CTD PMID:25969534 NCBI chr10:73,902,210...73,902,301
Ensembl chr10:73,902,210...73,902,301
JBrowse link
G Mir222 microRNA 222 multiple interactions ISO RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased expression of MIR222 mRNA] CTD PMID:32006662 NCBI chr  X:3,683,919...3,684,021
Ensembl chr  X:3,683,919...3,684,021
JBrowse link
G Mmp1 matrix metallopeptidase 1 multiple interactions ISO RTKI cpd inhibits the reaction [EGF protein results in increased secretion of MMP1 protein]; RTKI cpd inhibits the reaction [Histamine results in increased expression of MMP1 mRNA]; RTKI cpd inhibits the reaction [Histamine results in increased secretion of MMP1 protein] CTD PMID:17656145 NCBI chr 8:5,703,206...5,723,593
Ensembl chr 8:5,703,206...5,723,591
JBrowse link
G Mmp13 matrix metallopeptidase 13 multiple interactions ISO RTKI cpd inhibits the reaction [Asbestos, Serpentine results in increased expression of MMP13 mRNA] CTD PMID:16571779 NCBI chr 8:5,522,739...5,533,018
Ensembl chr 8:5,522,739...5,533,018
JBrowse link
G Mmp14 matrix metallopeptidase 14 multiple interactions ISO RTKI cpd inhibits the reaction [Acrolein results in increased expression of MMP14 mRNA] CTD PMID:19661247 NCBI chr15:33,074,441...33,083,666
Ensembl chr15:33,074,441...33,083,655
JBrowse link
G Mmp2 matrix metallopeptidase 2 multiple interactions ISO RTKI cpd inhibits the reaction [bisphenol A results in increased expression of MMP2 protein]; RTKI cpd inhibits the reaction [Hexachlorobenzene results in increased expression of MMP2 protein] CTD PMID:23462309, PMID:25312822 NCBI chr19:15,542,771...15,570,589
Ensembl chr19:15,542,765...15,570,611
JBrowse link
G Mmp7 matrix metallopeptidase 7 multiple interactions ISO RTKI cpd inhibits the reaction [antimonite results in increased expression of MMP7 mRNA]; RTKI cpd inhibits the reaction [arsenite results in increased expression of MMP7 mRNA] CTD PMID:17400267 NCBI chr 8:5,893,253...5,900,965
Ensembl chr 8:5,893,249...5,901,049
JBrowse link
G Mmp9 matrix metallopeptidase 9 multiple interactions ISO RTKI cpd inhibits the reaction [Acrolein results in increased expression of MMP9 mRNA]; RTKI cpd inhibits the reaction [bisphenol A results in increased expression of MMP9 protein]; RTKI cpd inhibits the reaction [Cadmium results in increased expression of MMP9 mRNA]; RTKI cpd inhibits the reaction [Hexachlorobenzene results in increased secretion of and results in increased activity of MMP9 protein]; RTKI cpd inhibits the reaction [sodium arsenite results in increased secretion of MMP9 protein] CTD PMID:15504454, PMID:18006877, PMID:23462309, PMID:25312822, PMID:26514923 NCBI chr 3:161,413,410...161,421,473
Ensembl chr 3:161,413,298...161,421,520
JBrowse link
G Mt2A metallothionein 2A multiple interactions ISO [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Cadmium Chloride results in increased expression of MT2 protein] CTD PMID:23376140 NCBI chr19:11,307,966...11,308,740
Ensembl chr19:11,307,967...11,308,740
JBrowse link
G Mtor mechanistic target of rapamycin kinase multiple interactions EXP RTKI cpd inhibits the reaction [7-ketocholesterol results in increased phosphorylation of MTOR protein]; RTKI cpd inhibits the reaction [cholesterol alpha-oxide results in increased phosphorylation of MTOR protein] CTD PMID:20466046 NCBI chr 5:165,263,813...165,373,967
Ensembl chr 5:165,263,800...165,373,967
JBrowse link
G Muc5ac mucin 5AC, oligomeric mucus/gel-forming multiple interactions ISO RTKI cpd inhibits the reaction [[Smoke results in increased abundance of Particulate Matter] which results in increased expression of MUC5AC mRNA]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased expression of MUC5AC mRNA]; RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased expression of MUC5AC protein]; RTKI cpd inhibits the reaction [Particulate Matter results in increased expression of MUC5AC mRNA]; RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of MUC5AC mRNA] CTD PMID:10640773, PMID:20971882, PMID:22820758, PMID:31944254 NCBI chr 1:214,725,482...214,756,653 JBrowse link
G Nfe2l2 nuclear factor, erythroid 2-like 2 multiple interactions ISO [2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one co-treated with RTKI cpd] inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein]; RTKI cpd inhibits the reaction [Pyocyanine affects the localization of NFE2L2 protein] CTD PMID:24015256 NCBI chr 3:62,497,568...62,525,146
Ensembl chr 3:62,497,571...62,524,996
JBrowse link
G Nfkbia NFKB inhibitor alpha increases expression ISO [RTKI cpd results in increased expression of CYLD protein] which results in increased expression of NFKBIA protein CTD PMID:21109933 NCBI chr 6:76,267,227...76,270,457
Ensembl chr 6:76,267,228...76,270,457
JBrowse link
G Nos3 nitric oxide synthase 3 multiple interactions ISO [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Equol results in increased phosphorylation of and results in increased activity of NOS3 protein] CTD PMID:21300668 NCBI chr 4:7,321,908...7,342,404
Ensembl chr 4:7,320,668...7,342,410
JBrowse link
G Notch1 notch receptor 1 multiple interactions
increases expression
ISO RTKI cpd inhibits the reaction [arsenite results in decreased expression of NOTCH1 protein modified form]; RTKI cpd inhibits the reaction [Cadmium Chloride results in increased cleavage of NOTCH1 protein]
RTKI cpd results in increased expression of NOTCH1 protein modified form
CTD PMID:18633435, PMID:25118938 NCBI chr 3:3,905,562...3,951,015
Ensembl chr 3:3,905,453...3,951,025
JBrowse link
G Nox4 NADPH oxidase 4 multiple interactions
increases expression
EXP Doxorubicin promotes the reaction [RTKI cpd results in increased expression of NOX4 mRNA] CTD PMID:18371937 NCBI chr 1:150,796,359...150,976,186
Ensembl chr 1:150,797,084...150,976,194
JBrowse link
G Nppa natriuretic peptide A multiple interactions EXP RTKI cpd inhibits the reaction [GNAQ protein promotes the reaction [Phenylephrine results in increased expression of NPPA protein]] CTD PMID:14676212 NCBI chr 5:164,808,407...164,809,716
Ensembl chr 5:164,808,323...164,809,705
JBrowse link
G Nts neurotensin multiple interactions ISO RTKI cpd inhibits the reaction [NTS protein results in increased expression of CXCL8 mRNA]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of EGFR protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [NTS protein results in increased secretion of CXCL8 protein] CTD PMID:15177934, PMID:15247267 NCBI chr 7:44,111,594...44,120,998
Ensembl chr 7:44,111,151...44,121,130
JBrowse link
G Pcna proliferating cell nuclear antigen decreases expression ISO RTKI cpd results in decreased expression of PCNA protein CTD PMID:15923621 NCBI chr 3:124,880,698...124,884,570
Ensembl chr 3:124,880,698...124,884,570
JBrowse link
G Pla2g4a phospholipase A2 group IVA multiple interactions ISO RTKI cpd inhibits the reaction [[lead nitrate results in increased expression of PLA2G4A mRNA] which results in increased secretion of Dinoprostone]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of PLA2G4A mRNA]
RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A mRNA]; RTKI cpd inhibits the reaction [Fluoxetine results in increased expression of PLA2G4A protein]
CTD PMID:19662385, PMID:20850495 NCBI chr13:67,062,252...67,206,688
Ensembl chr13:66,988,937...67,206,693
JBrowse link
G Ppard peroxisome proliferator-activated receptor delta multiple interactions ISO RTKI cpd inhibits the reaction [antimonite results in increased expression of PPARD mRNA]; RTKI cpd inhibits the reaction [arsenite results in increased expression of PPARD mRNA] CTD PMID:17400267 NCBI chr20:7,818,289...7,883,482
Ensembl chr20:7,818,289...7,885,333
JBrowse link
G Pparg peroxisome proliferator-activated receptor gamma multiple interactions ISO RTKI cpd inhibits the reaction [bisphenol A results in increased expression of PPARG mRNA] CTD PMID:31075703 NCBI chr 4:147,274,055...147,399,383
Ensembl chr 4:147,274,107...147,399,380
JBrowse link
G Prkca protein kinase C, alpha multiple interactions ISO RTKI cpd inhibits the reaction [evodiamine results in increased phosphorylation of PRKCA protein] CTD PMID:19854188 NCBI chr10:96,186,509...96,585,168
Ensembl chr10:96,191,133...96,584,947
JBrowse link
G Prkcd protein kinase C, delta multiple interactions ISO RTKI cpd inhibits the reaction [sodium arsenite affects the expression of PRKCD protein]; RTKI cpd inhibits the reaction [sodium arsenite results in decreased phosphorylation of PRKCD protein] CTD PMID:20082316 NCBI chr16:6,655,131...6,675,746
Ensembl chr16:6,655,120...6,675,746
JBrowse link
G Ptgs2 prostaglandin-endoperoxide synthase 2 multiple interactions ISO
EXP
RTKI cpd inhibits the reaction [[lead nitrate results in increased expression of PTGS2 mRNA] which results in increased secretion of Dinoprostone]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of PTGS2 mRNA]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of PTGS2 protein]
RTKI cpd inhibits the reaction [LHB protein results in increased expression of PTGS2 mRNA]
RTKI cpd inhibits the reaction [TRPV1 gene mutant form promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of PTGS2 protein]]
CTD PMID:15459120, PMID:20660715, PMID:20850495, PMID:24639330 NCBI chr13:67,351,230...67,356,920
Ensembl chr13:67,351,087...67,359,335
JBrowse link
G Ptk2 protein tyrosine kinase 2 multiple interactions ISO [RTKI cpd co-treated with bisphenol A] results in increased phosphorylation of PTK2 protein CTD PMID:32325111 NCBI chr 7:114,436,419...114,611,317
Ensembl chr 7:114,437,361...114,590,119
JBrowse link
G Rb1 RB transcriptional corepressor 1 multiple interactions ISO RTKI cpd inhibits the reaction [lead nitrate results in increased expression of RB1 mRNA]; RTKI cpd inhibits the reaction [lead nitrate results in increased expression of RB1 protein] CTD PMID:24639330 NCBI chr15:55,081,582...55,209,060
Ensembl chr15:55,083,140...55,209,342
JBrowse link
G Runx2 RUNX family transcription factor 2 decreases expression EXP RTKI cpd results in decreased expression of RUNX2 mRNA CTD PMID:20197312 NCBI chr 9:18,564,743...18,773,092
Ensembl chr 9:18,564,927...18,773,092
JBrowse link
G Shc1 SHC adaptor protein 1 multiple interactions EXP RTKI cpd inhibits the reaction [Hydrogen Peroxide results in increased phosphorylation of SHC1 protein alternative form]; RTKI cpd inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; RTKI cpd inhibits the reaction [sodium arsenite promotes the reaction [SHC1 protein modified form binds to EGFR protein binds to GRB protein]]; RTKI cpd inhibits the reaction [sodium arsenite results in increased phosphorylation of SHC1 protein] CTD PMID:9710602, PMID:19168439 NCBI chr 2:188,745,503...188,757,066
Ensembl chr 2:188,745,503...188,757,066
JBrowse link
G Slc1a2 solute carrier family 1 member 2 multiple interactions EXP RTKI cpd inhibits the reaction [4,4',4''-(4-propyl-((1)H)-pyrazole-1,3,5-triyl) tris-phenol results in increased expression of SLC1A2 protein]; RTKI cpd inhibits the reaction [[1-(4-(6-bromobenzo(1,3)dioxol-5-yl)-3a,4,5,9b-tetrahydro-3H-cyclopenta(c)quinolin-8-yl)ethanone binds to and results in increased activity of GPER1 protein] which results in increased expression of SLC1A2 protein]; RTKI cpd inhibits the reaction [diarylpropionitrile results in increased expression of SLC1A2 protein]; RTKI cpd inhibits the reaction [Raloxifene Hydrochloride results in increased expression of SLC1A2 mRNA]; RTKI cpd inhibits the reaction [Raloxifene Hydrochloride results in increased expression of SLC1A2 protein] CTD PMID:22645130, PMID:24782323 NCBI chr 3:92,518,679...92,665,731
Ensembl chr 3:92,640,752...92,665,644
JBrowse link
G Sp1 Sp1 transcription factor multiple interactions EXP RTKI cpd inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]]; RTKI cpd inhibits the reaction [AGT protein results in increased expression of SP1 mRNA] CTD PMID:25398788 NCBI chr 7:144,014,173...144,044,635
Ensembl chr 7:144,014,173...144,044,629
JBrowse link
G Src SRC proto-oncogene, non-receptor tyrosine kinase multiple interactions ISO
EXP
[[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]
RTKI cpd inhibits the reaction [estradiol-17 beta-glucuronide results in increased phosphorylation of and results in increased activity of SRC protein]
RTKI cpd inhibits the reaction [EGF protein results in increased phosphorylation of SRC protein]; RTKI cpd inhibits the reaction [Nicotine results in increased phosphorylation of SRC protein]
CTD PMID:14569062, PMID:23376140, PMID:25813982, PMID:25856345 NCBI chr 3:153,547,807...153,595,643
Ensembl chr 3:153,580,861...153,595,642
JBrowse link
G Srebf1 sterol regulatory element binding transcription factor 1 multiple interactions EXP RTKI cpd inhibits the reaction [Glucose results in increased activity of and results in increased cleavage of SREBF1 protein] CTD PMID:22031849 NCBI chr10:46,570,996...46,593,021
Ensembl chr10:46,570,996...46,593,009
JBrowse link
G Star steroidogenic acute regulatory protein multiple interactions ISO RTKI cpd inhibits the reaction [bisphenol A results in increased expression of STAR mRNA] CTD PMID:31075703 NCBI chr16:71,036,204...71,040,847
Ensembl chr16:71,036,204...71,040,847
JBrowse link
G Stat3 signal transducer and activator of transcription 3 multiple interactions
decreases expression
ISO RTKI cpd inhibits the reaction [bisphenol A results in increased expression of STAT3 mRNA]; RTKI cpd inhibits the reaction [EGF protein results in increased activity of STAT3 protein]
RTKI cpd results in decreased expression of STAT3 protein modified form
[[RTKI cpd results in decreased activity of EGFR protein] co-treated with [SU 6656 results in decreased activity of SRC protein]] inhibits the reaction [Cadmium Chloride results in increased phosphorylation of and results in increased activity of STAT3 protein]; [RTKI cpd results in decreased activity of EGFR protein] which results in decreased phosphorylation of STAT3 protein
CTD PMID:21268125, PMID:21909620, PMID:23376140, PMID:25841994, PMID:29974605 NCBI chr10:88,790,401...88,842,263
Ensembl chr10:88,790,408...88,842,233
JBrowse link
G Stat5b signal transducer and activator of transcription 5B multiple interactions ISO [RTKI cpd results in decreased activity of EGFR protein] inhibits the reaction [Hexachlorobenzene results in increased phosphorylation of and results in increased activity of STAT5B protein] CTD PMID:21205633 NCBI chr10:88,686,207...88,712,313
Ensembl chr10:88,686,207...88,754,829
JBrowse link
G Tac1 tachykinin, precursor 1 multiple interactions ISO RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [TAC1 protein results in increased phosphorylation of and results in increased activity of MAPK3 protein] CTD PMID:15319441 NCBI chr 4:33,638,853...33,646,819
Ensembl chr 4:33,638,709...33,646,819
JBrowse link
G Tfap2a transcription factor AP-2 alpha multiple interactions ISO RTKI cpd inhibits the reaction [butylbenzyl phthalate affects the localization of TFAP2A protein]; RTKI cpd inhibits the reaction [Dibutyl Phthalate affects the localization of TFAP2A protein] CTD PMID:22552774 NCBI chr17:24,653,342...24,670,457
Ensembl chr17:24,654,902...24,670,457
JBrowse link
G Tgfa transforming growth factor alpha multiple interactions ISO RTKI cpd inhibits the reaction [Particulate Matter results in increased secretion of TGFA protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of FOS protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased expression of GPER1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of AKT1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RTKI cpd inhibits the reaction [TGFA protein results in increased phosphorylation of and results in increased activity of MAPK3 protein]; RTKI cpd inhibits the reaction [Vehicle Emissions results in increased secretion of TGFA protein] CTD PMID:11309286, PMID:19749156, PMID:24555532 NCBI chr 4:117,961,877...118,045,923
Ensembl chr 4:117,962,319...118,046,344
JBrowse link
G Tgfb1 transforming growth factor, beta 1 multiple interactions EXP RTKI cpd inhibits the reaction [AGT protein promotes the reaction [SP1 protein binds to TGFB1 promoter]] CTD PMID:25398788 NCBI chr 1:82,480,875...82,497,196
Ensembl chr 1:82,480,195...82,497,199
JBrowse link
G Tnf tumor necrosis factor multiple interactions ISO RTKI cpd inhibits the reaction [Poly I-C results in increased secretion of TNF protein] CTD PMID:20932985 NCBI chr20:5,189,382...5,192,000
Ensembl chr20:5,189,390...5,192,000
JBrowse link
G Tnfaip6 TNF alpha induced protein 6 multiple interactions EXP RTKI cpd inhibits the reaction [LHB protein results in increased expression of TNFAIP6 mRNA] CTD PMID:15459120 NCBI chr 3:37,545,238...37,564,704
Ensembl chr 3:37,545,238...37,564,699
JBrowse link
G Tp53 tumor protein p53 multiple interactions ISO RTKI cpd inhibits the reaction [sodium arsenite results in increased expression of TP53 protein] CTD PMID:15734884 NCBI chr10:56,186,299...56,198,449
Ensembl chr10:56,187,020...56,198,449
JBrowse link
G Trpv1 transient receptor potential cation channel, subfamily V, member 1 multiple interactions ISO RTKI cpd inhibits the reaction [TRPV1 gene mutant form promotes the reaction [[Tetradecanoylphorbol Acetate co-treated with Capsaicin] results in increased expression of PTGS2 protein]] CTD PMID:20660715 NCBI chr10:59,799,123...59,824,208
Ensembl chr10:59,799,123...59,824,679
JBrowse link
G Vegfa vascular endothelial growth factor A multiple interactions ISO RTKI cpd inhibits the reaction [Asbestos, Crocidolite results in increased secretion of VEGFA protein]; RTKI cpd inhibits the reaction [calcium silicate results in increased secretion of VEGFA protein] CTD PMID:21762757 NCBI chr 9:17,340,341...17,355,681
Ensembl chr 9:17,340,341...17,355,681
JBrowse link
G Vim vimentin decreases expression
multiple interactions
ISO RTKI cpd results in decreased expression of VIM protein
RTKI cpd inhibits the reaction [Tetrachlorodibenzodioxin results in increased expression of VIM protein]
CTD PMID:25856345, PMID:26971374 NCBI chr17:80,882,715...80,891,200
Ensembl chr17:80,882,666...80,891,212
JBrowse link

Term paths to the root
Path 1
Term Annotations click to browse term
  CHEBI ontology 19816
    role 19764
      biological role 19764
        pharmacological role 18825
          antagonist 16213
            epidermal growth factor receptor antagonist 309
              N-\{4-[(3-bromophenyl)amino]quinazolin-6-yl\}but-2-ynamide 0
              PD 168393 19
              PD-153035 0
              PD-153035 hydrochloride 0
              dacomitinib 1
              erlotinib + 127
              gefitinib + 149
              osimertinib 13
              osimertinib mesylate 0
              sapitinib 0
              semicochliodinol A 0
              semicochliodinol B 0
              tyrphostin AG 1478 118
              tyrphostin AG 825 0
Path 2
Term Annotations click to browse term
  CHEBI ontology 19816
    role 19764
      biological role 19764
        inhibitor 18247
          enzyme inhibitor 18173
            EC 2.* (transferase) inhibitor 13825
              EC 2.7.* (P-containing group transferase) inhibitor 13505
                protein kinase inhibitor 13032
                  epidermal growth factor receptor antagonist 309
                    N-\{4-[(3-bromophenyl)amino]quinazolin-6-yl\}but-2-ynamide 0
                    PD 168393 19
                    PD-153035 0
                    PD-153035 hydrochloride 0
                    dacomitinib 1
                    erlotinib + 127
                    gefitinib + 149
                    osimertinib 13
                    osimertinib mesylate 0
                    sapitinib 0
                    semicochliodinol A 0
                    semicochliodinol B 0
                    tyrphostin AG 1478 118
                    tyrphostin AG 825 0
paths to the root

NHLBI Logo

RGD is funded by grant HL64541 from the National Heart, Lung, and Blood Institute on behalf of the NIH.